Original Article
Effects of Human Growth Hormone in Men over 60 Years Old
N Engl J Med 1990; 323:1-6July 5, 1990
- Abstract
- Abstract
Background.
The declining activity of the growth hormone-insulin-like growth factor I (IGF-I) axis with advancing age may contribute to the decrease in lean body mass and the increase in mass of adipose tissue that occur with aging.
Methods.
To test this hypothesis, we studied 21 healthy men from 61 to 81 years old who had plasma IGF-I concentrations of less than 350 U per liter during a six-month base-line period and a six-month treatment period that followed. During the treatment period, 12 men (group 1) received approximately 0.03 mg of biosynthetic human growth hormone per kilogram of body weight subcutaneously three times a week, and 9 men (group 2) received no treatment. Plasma IGF-I levels were measured monthly. At the end of each period we measured lean body mass, the mass of adipose tissue, skin thickness (epidermis plus dermis), and bone density at nine skeletal sites. In group 1, the mean plasma IGF-I level rose into the youthful range of 500 to 1500 U per liter during treatment, whereas in group 2 it remained below 350 U per liter. The administration of human growth hormone for six months in group 1 was accompanied by an 8.8 percent increase in lean body mass, a 14.4 percent decrease in adipose-tissue mass, and a 1.6 percent increase in average lumbar vertebral bone density (P<0.05 in each instance). Skin thickness increased 7.1 percent (P = 0.07). There was no significant change in the bone density of the radius or proximal femur. In group 2 there was no significant change in lean body mass, the mass of adipose tissue, skin thickness, or bone density during treatment.
Results.
Conclusions.
Diminished secretion of growth hormone is responsible in part for the decrease of lean body mass, the expansion of adipose-tissue mass, and the thinning of the skin that occur in old age. (N Engl J Med 1990; 323:1–6.)
Media in This Article
Table 1
Schedule of Tests during the Base-Line and Treatment Periods.Table 2
Clinical Characteristics of the Study Subjects.Article Activity
- Article
IN middle and late adulthood all people experience a series of progressive alterations in body composition.1 The lean body mass shrinks and the mass of adipose tissue expands. The contraction in lean body mass reflects atrophic processes in skeletal muscle, liver, kidney, spleen, skin, and bone.
These structural changes have been considered unavoidable results of aging.1 It has recently been proposed, however, that reduced availability of growth hormone in late adulthood may contribute to such changes.1 , 2 This proposal is based on two lines of evidence. First, after about the age of 30, the secretion of growth hormone by the pituitary gland tends to decline.1 , 3 , 4 Since growth hormone is secreted in pulses, mostly during the early hours of sleep, it is difficult to measure the 24-hour secretion of the substance directly. Growth hormone secretion can be measured indirectly, however, by measuring the plasma concentration of insulin-like growth factor I (IGF-I, also known as somatomedin C), which is produced and released by the liver and perhaps other tissues in response to growth hormone.5 There is little diurnal variation in the plasma IGF-I concentration, and measurements of it are therefore a convenient indicator of growth hormone secretion.5 Plasma IFG-I concentrations decline with advancing age in healthy adults.1 , 4 , 6 Less than 5 percent of the healthy men 20 to 40 years old have plasma IGF-1 values of less than 350 U per liter, but the values are below this figure in 30 percent of the healthy men over 60.4 Likewise, the nocturnal pulses of growth hormone secretion become smaller or disappear with advanced age. If the plasma concentration of IGF-I falls below 350 U per liter in older adults, no spontaneous circulating pulses of growth hormone can be detected by currently available radioimmunoassay methods.4 The concomitant decline in plasma concentrations of both hormones supports the view that the decrease in IGF-I results from diminished growth hormone secretion.4 , 6 Second, diminished secretion of growth hormone is accompanied not only by a fall in the plasma IGF-I concentration, but also by atrophy of the lean body mass and expansion of the mass of adipose tissue.1 These alterations in body composition caused by growth hormone deficiency can be reversed by replacement doses of the hormone, as experiments in rodents,7 children,8 , 9 and adults 20 to 50 years old10 11 12 13 have shown. These findings suggest that the atrophy of the lean body mass and its component organs and the enlargement of the mass of adipose tissue that are characteristic of the elderly result at least in part from diminished secretion of growth hormone.1 , 2 If so, the age-related changes in body composition should be correctable in part by the administration of human growth hormone, now readily available as a biosynthetic product.14
In this study we administered biosynthetic human growth hormone for six months to 12 healthy men from 61 to 81 years old whose plasma IGF-I concentrations were below 350 U per liter, and we measured the effects on plasma IGF-I concentration, lean body mass, adipose-tissue mass, skin (dermal plus epidermal) thickness, regional bone density, and mandibular-height ratio (the height of the alveolar ridge divided by the total height of the mandible). The measurement of the mandible was included to test the hypothesis that the age-related involution of dental bone results in part from the loss of stimulation by growth hormone.1 In addition, the men were monitored for possible adverse effects of the hormone by means of interviews, physical examinations, and standard laboratory tests. Nine men matched for age and with similar plasma IGF-I concentrations served as controls.
Methods
Subjects
Healthy men who were 61 or older and living in the community were recruited through newspaper advertisements followed by an interview. Entry criteria (available from the authors on request) included body weight of 90 to 120 percent of the standard for age, the ability to administer growth hormone to oneself subcutaneously, and the absence of indications of major disease. Ninety-five men who answered the advertisements met criteria that could be ascertained by interview. Their plasma IGF-I concentrations were then determined twice at an interval of four weeks. Consistent with the results of a previous study,13 the plasma IGF-I values in these men ranged from 100 to 2400 U per liter, with an average of 500 U per liter. Thirty-three of the men had plasma IGF-I values of less than 350 U per liter on both occasions. These 33 men were then further evaluated by a medical-history taking, physical examination, differential blood count, urinalysis, blood-chemistry tests, chest radiography, and electrocardiography. Twenty-six subjects (1 black and 25 white) met all the entry criteria and were enrolled in the 12-month protocol summarized in Table 1Table 1
Schedule of Tests during the Base-Line and Treatment Periods..Study Periods
The men were seen at regular intervals and tested as shown in Table 1 during the first week of the first, third, and sixth months of the base-line period. Five men dropped out of the study during these six months (four for personal reasons and one because carcinoma of the prostate was detected).
At the beginning of the seventh month, the 21 men who had completed the base-line period were randomly assigned to group 1 (growth hormone group) or group 2 (control group) in a ratio of 3 to 2. The randomization table was generated by a computer program such that in each group of five men, three would be assigned to the growth hormone group and two to the control group. All 21 men (12 in group 1 and 9 in group 2) completed the treatment period and constitute the study group for this report. Their clinical characteristics are summarized in Table 2Table 2
Clinical Characteristics of the Study Subjects.. During the first week of the seventh month, the men in group 1 were instructed in the subcutaneous administration of recombinant biosynthetic human growth hormone (2.6 IU per milligram of hormone; Eli Lilly). The initial dose was 0.03 mg per kilogram of body weight, injected three times a week at 8 a.m., the interval between injections being either one or two days. A sample of venous blood for plasma IGF-I assay was obtained each month 24 hours after a growth hormone injection. If the IGF-I level was below 500 U per liter, the dose of hormone was increased by 25 percent; if the IGF-I level was above 1500 U per liter, the dose was reduced by 25 percent. The men in group 2 received no injections. The schedule of tests for both groups during the treatment period is shown in Table 1.At the start of the base-line period, the project dietitian instructed each man to follow a diet that furnished 25 to 30 kcal per kilogram. The distribution of kilocalories among protein, carbohydrate, and fat was approximately 15 percent, 50 percent, and 35 percent, respectively. At each scheduled visit shown in Table 1, the dietitian analyzed each man's diet on the basis of a 24-hour dietary recall and instructed the subjects again about the standard diet. The men were told not to alter their lifestyles (including their use of tobacco or alcohol and their level of physical activity) during the 12-month study period.
The study protocol was carried out with the informed consent of each subject and with the approval of the human-research committees of the Medical College of Wisconsin, the Chicago Medical School, and the Veterans Affairs Medical Centers in North Chicago and Milwaukee.
Statistical Analysis
The methods used to measure each response variable and the locations where the tests were performed are described in Table 1. The interassay coefficients of variation for the response variables were as follows: plasma IGF-I, 7.2 percent; lean body mass, 3.6 percent; adipose-tissue mass, 6.9 percent; skin thickness, 5.4 percent; and bone density, 2.3 percent (average of nine measured sites).
P values based on two-tailed, matched-pair t-tests were calculated for the comparisons between the 6-month and 12-month values in group 1 and group 2. In addition, for each response variable the 6-month value was subtracted from the 12-month value to represent the change in each subject. P values based on two-tailed, unequal-variance, independent-sample t-tests were then calculated for the comparison of the changes in response variables between groups 1 and 2.
Results
Clinical Observations
All the men remained healthy, and none had any changes in the results of differential blood count, urinalysis, blood-chemistry profile, chest radiography, electrocardiography, or echocardiography during the 12-month protocol. Specifically, none had edema, fasting hyperglycemia (>6.6 mmol of glucose per liter), an increase in blood pressure to more than 160/90 mm Hg, ventricular hypertrophy, or a local reaction to human growth hormone, nor did their serum cholesterol or triglyceride concentrations change significantly. In group 1, however, both the mean (±SE) systolic blood pressure and fasting plasma glucose concentration were significantly higher (P<0.05 by matched-pair t-test) at the end of the experimental period than at the end of the base-line period (127.2±5.2 vs. 119.1±3.6 mm Hg and 5.8±0.2 vs. 5.4±0.2 mmol per liter, respectively).
Plasma IGF-I Concentration
In group 1, the mean plasma IGF-I concentration ranged from 200 to 250 U per liter throughout the base-line period (Table 3Table 3
Effect of the Administration of Human Growth Hormone on Plasma IGF-I Concentrations in Healthy Older Men.*). Within one month after the administration of growth hormone had been initiated, the mean IGF-I level rose to 830 U per liter (P<0.05), and it remained near this value for the next five months. Eight of the 12 men in group 1 required no adjustment in their initial dose of growth hormone. Two required an upward adjustment of 25 percent, and two required a downward adjustment of 25 percent. The mean plasma IGF-I concentration in group 2 remained in the range of 180 to 300 U per liter throughout the base-line and treatment periods.Lean Body Mass, Adipose-Tissue Mass, Skin Thickness, Bone Density, and Mandibular-Height Ratio
Table 4Table 4
Effect of the Administration of Human Growth Hormone on Weight, Lean Body Mass, Adipose-Tissue Mass, Skin Thickness, and Bone Density in Healthy Older Men.* shows the mean values for the other response variables at the end of the base-line period (6 months) and the end of the treatment period (12 months). There was no significant change in weight in either group. In group 1, several response variables had changed significantly after 12 months. Lean body mass and the average density of the lumbar vertebrae increased by 8.8 percent (P<0.0005) and 1.6 percent (P<0.04), respectively, and adipose-tissue mass decreased by 14.4 percent (P<0.005). The sum of skin thicknesses at four sites increased 7.1 percent (P = 0.07). The small average change in lumbar vertebral bone density (only 0.02 g per square centimeter) was statistically significant because of very little variability in individual results. The bone density of the radius and proximal femur and the ratio of the height of the alveolar ridge to total mandibular height did not change significantly. In group 2 none of these variables changed significantly. The change in the lean body mass was significantly greater in group 1 than in group 2 (P<0.018), but the differences in changes in skin thickness and adipose-tissue mass between groups did not reach statistical significance in this small series (P = 0.10 and 0.13, respectively).Discussion
The 21 men studied were representative of the approximately one third of all men 60 to 80 years old who have plasma IGF-I concentrations of less than 350 U per liter (as compared with a range of 500 to 1500 U per liter in healthy men 20 to 40 years old).4 Our findings cannot be generalized to the approximately two thirds of all men over 60 who have plasma IGF-I concentrations of more than 350 U per liter or to women of a similar age. Furthermore, our entry criteria focused the study on an overtly healthy subgroup of older men.
In the absence of obesity,4 below-normal weight,20 or liver disease,21 a plasma IGF-I concentration of less than 350 U per liter in older men generally signifies that they secrete very little growth hormone.4 To verify this explanation for the low plasma IGF-I concentration in these men, it would be necessary to measure serum growth hormone levels at frequent intervals for 24 hours or to determine the 24-hour urinary excretion of growth hormone. We did not do this, but Ho et al. found that the 24-hour integrated serum growth hormone level was markedly lower in the men over 55 than in men 18 to 33 years old.22 An alternative explanation for a low plasma IGF-I concentration is decreased production of plasma IGF-I binding proteins. Most of the IGF-I plasma is bound to these proteins, but their concentrations vary little in healthy people who eat a normal diet.
In the 12 men in group 1, initially low plasma IGF-I concentrations were raised to the normal range for young adult men by the dose of growth hormone administered, with no evidence of tachyphylaxis or hormone resistance. The dose, approximately 0.03 mg per kilogram three times a week, was based on published estimates of the rate of growth hormone secretion in young men23 and was comparable to or smaller than doses given previously to children with growth hormone deficiency24 , 25 and young adults.10 11 12 13 The plasma IGF-I responses to this dose in these older men were similar in magnitude to those in younger people. That "replacement" rather than pharmacologic doses were being administered was confirmed by the plasma IGF-I measurements, which remained within the range for healthy young adults (500 to 1500 U per liter) throughout the treatment period (Table 3). We conclude that in aging men with low plasma IGF-I concentrations hepatic responsiveness to human growth hormone is not impaired, and the decline in plasma IGF-I concentrations in such men results from growth hormone deficiency rather than growth hormone resistance. The increase in plasma IGF-I levels that occurs when growth hormone is administered to children with growth hormone deficiency reflects not only augmented hepatic production of IGF-I, but also increased production of one of the binding proteins that transport IGF-I.26 The extent to which the production of IGF-I binding protein is increased by the administration of growth hormone has not yet been studied in adults.
At the beginning of our study, adverse reactions to human growth hormone were thought to be unlikely because physiologic doses were being used. Furthermore, similar or larger doses have not caused undesired reactions in children or young adults.10 11 12 13 14 , 25 Nevertheless, it remained possible that this dose, when given for six months to older subjects, might cause some manifestation of hypersomatotropism, such as edema, hypertension, diabetes, or cardiomegaly.27 28 29 Although none of these conditions developed, there were small increases in the mean systolic blood pressure and fasting plasma glucose concentration of the group of men who received growth hormone.
The magnitude of the increases in lean body mass and the decreases in adipose-tissue mass (8.8 and -14.2 percent above and below base line, respectively) in the aging men who received human growth hormone for six months was similar to the magnitude of these responses in children8 , 9 and young adults10 11 12 13 treated with similar or lower doses for three to six months, a comparison that provides further evidence that tissue responsiveness to growth hormone and IGF-I is not altered in older men. Until now, the evidence for such a conclusion came only from short-term nitrogen-balance experiments.14 , 30 31 32
Salomon et al. reported that the administration of human growth hormone in a dose of 0.49 unit per kilogram per week (0.19 mg per kilogram per week) for six months to adults 20 to 50 years old who had growth hormone deficiency lowered the serum cholesterol concentration significantly.13 Serum cholesterol concentrations did not change in our study, in which the dose of growth hormone was about half as large (0.9 mg per kilogram per week). The divergent results could reflect differences in the subjects' ages, the degree of growth hormone deficiency, the dose of hormone, or all three.
In rodents, the increase in lean body mass in response to growth hormone is due to increases in the volume of skeletal muscle, skin, liver, kidney, and spleen.1 , 7 In young human subjects, an enlargement of muscle and kidney induced by growth hormone has been documented8 9 10 11 12; other organs have not yet been assessed. The reduction in adipose-tissue mass when children with growth hormone deficiency are treated with human growth hormone is associated with a redistribution of adipose tissue from abdominal to peripheral areas.31 It is not known, however, whether the increase in lean body mass and the decrease in adipose-tissue mass are qualitatively as well as quantitatively similar in old and young human subjects.
Biosynthetic human growth hormone had no detectable effect on the bone density of the radius or proximal femur in the aging men, but it increased the density of the lumbar vertebrae by about 1.6 percent. Although the decrease in bone density with advancing age in men may be due in part to diminished secretion of growth hormone,1 , 33 longer periods of administration of human growth hormone will be required before a final conclusion can be drawn regarding its efficacy in reversing that decrease. A similar interpretation applies to the lack of increase in the mandibular-height ratio.
The findings in this study are consistent with the hypothesis that the decrease in lean body mass, the increase in adipose-tissue mass, and the thinning of the skin that occur in older men are caused in part by reduced activity of the growth hormone—IGF-I axis, and can be restored in part by the administration of human growth hormone.1 , 2 The effects of six months of human growth hormone on lean body mass and adipose-tissue mass were equivalent in magnitude to the changes incurred during 10 to 20 years of aging.1 , 34 , 35 Among the questions that remain to be addressed are the following: What will be the benefits and what will be the nature and frequency of any adverse effects when larger numbers of elderly subjects and other doses of human growth hormone are studied? What organs are responsible for the increase in lean body mass, and do their functional capacities change as well? Only when such questions are answered can the possible benefits of human growth hormone in the elderly be explored. Since atrophy of muscle and skin contributes to the frailty of older people, the potential benefits of growth hormone merit continuing attention and investigation.
Supported by grants from the Department of Veterans Affairs and Eli Lilly and Co., and by a grant (1D31 PE95008–02) from the Public Health Service.
We are indebted to Dr. Ruth Hartmann, Milwaukee Veterans Affairs Medical Center, for assistance in the preparation of this report.
Source Information
From the Department of Medicine, Medical College of Wisconsin. Milwaukee (D.R., I.W.R.); the Medical Service. Veterans Affairs Medical Center, Milwaukee (D.R.); the Department of Medicine, Chicago Medical School. North Chicago (A.G.F., H.S.N., G.A.G., P.Y.L., L.C.); the Medicine (A.G.F., H.S.N., P.Y.L.), Nuclear Medicine (G.A.G.), and Dental (A.F.G.) Services. Veterans Affairs Medical Center, North Chicago; the Argonne National Laboratory, Argonne, Ill. (R.A.S.); and the Epidemiology-Biometry Program. University of Illinois School of Public Health, Chicago (D.B.M.).
- References
References
1
Rudman
Web of Science | Medline2
Meites
CrossRef | Web of Science | Medline3
Finkelstein
CrossRef | Web of Science | Medline4
Rudman
CrossRef | Web of Science | Medline5
Gemmons
CrossRef | Medline6
Florini
Medline7
van Buul-Offers
Medline8
Parra
CrossRef | Web of Science | Medline9
van der Werff ten Bosch
Web of Science | Medline10
Crist
CrossRef | Web of Science | Medline11
Jørgensen
CrossRef | Web of Science | Medline12
Crist
Web of Science | Medline13
Salomon
Full Text | Web of Science | Medline14
Jones AJS, O'Connor JV. Chemical characterization of methionyl human growth hormone. In: Hormone drugs: proceedings of the FDA-USP Workshop on Drug and Reference Standards for Insulins, Somatropins, and Thyroid-axis Hormones, Bethesda, Maryland, May 19–21, 1982. Rockville, Md.: United States Pharmacopeial Convention, 1982:335–51.
15
Flynn
Web of Science | Medline16
Lawrence
CrossRef | Web of Science | Medline17
Nagraj
Web of Science | Medline18
Goldberg
CrossRef | Medline19
Furlanetto
CrossRef | Web of Science | Medline20
Unterman
CrossRef | Web of Science | Medline21
Hall
CrossRef | Web of Science22
Ho
CrossRef | Web of Science | Medline23
Thompson
CrossRef | Web of Science | Medline24
Bierich
CrossRef | Medline25
Gunnarsson
CrossRef | Medline26
Hintz
CrossRef | Medline27
Ikkos 28
Penney
CrossRef | Web of Science | Medline29
Rizza
CrossRef | Web of Science | Medline30
Binnerts
CrossRef | Web of Science | Medline31
Rosenbaum
CrossRef | Web of Science | Medline32
Marcus
CrossRef | Web of Science | Medline33
Kelly
CrossRef | Web of Science | Medline34
Novak
Medline35
Shuster
CrossRef | Web of Science | Medline
- Citing Articles (379)
Citing Articles
1
2012. Human Growth Hormone and Insulin-Like Growth Factor. , 334-350.
CrossRef2
Marcello Maggio, E. Dall’Aglio, F. Lauretani, C. Cattabiani, G. Ceresini, P. Caffarra, G. Valenti, R. Volpi, A. Vignali, G. Schiavi, G. P. Ceda. (2012) The hormonal pathway to cognitive impairment in older men. The journal of nutrition, health & aging 16:1, 40-54
CrossRef3
Francisco J.A. de Paula, Clifford J. Rosen. (2011) Vitamin D Safety and Requirements. Archives of Biochemistry and Biophysics
CrossRef4
M. C. Mitterberger, M. Mattesich, E. Klaver, H. Piza-Katzer, W. Zwerschke. (2011) Reduced Insulin-Like Growth Factor-I Serum Levels in Formerly Obese Women Subjected to Laparoscopic-Adjustable Gastric Banding or Diet-Induced Long-term Caloric Restriction. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 66A:11, 1169-1177
CrossRef5
Arthur T. Fort. (2011) State of the Art in Anti-Aging Trends. Clinics in Geriatric Medicine 27:4, 507-522
CrossRef6
Benjamin D Horne. (2011) Is periodic fasting really good for reducing cardiovascular risk and improving heart health?. Future Cardiology 7:6, 721-724
CrossRef7
Emily P. Peron, Shelly L. Gray, Joseph T. Hanlon. (2011) Medication Use and Functional Status Decline in Older Adults: A Narrative Review. The American Journal of Geriatric Pharmacotherapy
CrossRef8
Andrew J Galpin, James R Bagley. (2011) Guiding Coaches Through Scientific Articles by Examining Human Growth Hormone Research. Strength and Conditioning Journal 33:5, 62-66
CrossRef9
(2011) Aplicaciones de la hormona del crecimiento en humanos. Medicina Clínica 137:10, 475-476
CrossRef10
Chenchen Peng, Lihong Wang, Zizhu Chen, Lei Ma, Yan Wei, Zhangfu Long. (2011) Construction of Porcine Growth Hormone Eukaryotic Expression Vector and Its Transfection Mediated by Cationic Liposome in Mice. Animal Biotechnology 22:4, 223-235
CrossRef11
Stéphane Walrand, Christelle Guillet, Jérome Salles, Noël Cano, Yves Boirie. (2011) Physiopathological Mechanism of Sarcopenia. Clinics in Geriatric Medicine 27:3, 365-385
CrossRef12
Fred R. Sattler, Shalender Bhasin, Jiaxiu He, Kevin E. Yarasheski, Ellen F. Binder, E. Todd Schroeder, Carmen Castaneda-Sceppa, Miwa Kawakubo, Ronenn Roubenoff, Matthew Dunn, Chris Hahn, Yolanda Stewart, Carmen Martinez, Stanley P. Azen. (2011) Durability of the effects of testosterone and growth hormone supplementation in older community-dwelling men: the HORMA Trial. Clinical Endocrinology 75:1, 103-111
CrossRef13
Rinaldo Guglielmi, Irene Misischi, Roberta Rinaldi, Enrico Papini. (2011) L’invecchiamento e il sistema endocrino. La Rivista Italiana della Medicina di Laboratorio - Italian Journal of Laboratory Medicine 7:2, 83-87
CrossRef14
Jeong Kyung Park, Jae Won Hong, Chang Oh Kim, Sang Woo Kim, Chi-Yeon Lim, Yoon-Sok Chung, Sung Woon Kim, Eun Jig Lee. (2011) SUSTAINED-RELEASE RECOMBINANT HUMAN GROWTH HORMONE IMPROVES BODY COMPOSITION AND QUALITY OF LIFE IN ADULTS WITH SOMATOPAUSE. Journal of the American Geriatrics Society 59:5, 944-947
CrossRef15
Peter Herbert Kann. (2011) Wachstumshormontherapie im Erwachsenenalter: Eine aktuelle Übersicht. Wiener klinische Wochenschrift 123:9-10, 259-267
CrossRef16
Assem M. Hossam Eldein, Sherif H. Elghamrawy, Saeeda M. Osman, Amal R. Elhak. (2011) Histological Evaluation of the Effect of Using Growth Hormone Around Immediate Dental Implants in Fresh Extraction Sockets: An Experimental Study. Implant Dentistry 20:1, 47-55
CrossRef17
Filippo Mulinacci, Martinus A.H. Capelle, Robert Gurny, Alex F. Drake, Tudor Arvinte. (2011) Stability of human growth hormone: Influence of methionine oxidation on thermal folding. Journal of Pharmaceutical Sciences 100:2, 451-463
CrossRef18
James F. Nelson. 2011. The Potential Role of Selected Endocrine Systems in Aging Processes. .
CrossRef19
H. Maurice Goodman. 2011. The Metabolic Actions of Growth Hormone. .
CrossRef20
Jeffrey B. Halter. 2011. Carbohydrate Metabolism. .
CrossRef21
David A. Fryburg, Eugene J. Barrett. 2011. The Regulation of Amino Acid and Protein Metabolism by Growth Hormone. .
CrossRef22
Sean Arkins, Rodney W. Johnson, Christian Minshall, Robert Dantzer, Keith W. Kelley. 2011. Immunophysiology: The Interaction of Hormones, Lymphohemopoietic Cytokines, and the Neuroimmune Axis. .
CrossRef23
Edward J. Masoro. 2011. Aging: Current Concepts. .
CrossRef24
Aleksandra Rojek, Marek Niedziela. (2011) Insulin receptor and its relationship with different forms of insulin resistance. Advances in Cell Biology 1:-1, 1-32
CrossRef25
Harold E. Carlson. 2011. Pituitary Function in Systemic Disorders. , 383-396.
CrossRef26
Marcus Simmgen. 2010. Neuroendocrinology of Ageing. , 45-50.
CrossRef27
Nilanjana Maulik, Gautam Maulik. 2010. Aging by Epigenetics. , 13-30.
CrossRef28
Susana Esteban, Celia Garau, Sara Aparicio, David Moranta, Pere Barceló, Margarita Ramis, Jesús A.F. Tresguerres, Rubén Rial. (2010) Improving Effects of Long-Term Growth Hormone Treatment on Monoaminergic Neurotransmission and Related Behavioral Tests in Aged Rats. Rejuvenation Research 13:6, 707-716
CrossRef29
Ilkka Sipilä, Harri Sintonen, Heikki Hietanen, Marjo Apajasalo, Soili Alanne, Anna-Mari Viita, Eeva Leinonen. (2010) Long-term effects of growth hormone therapy on patients with Prader-Willi syndrome. Acta Paediatrica 99:11, 1712-1718
CrossRef30
Jesús Devesa, Pablo Devesa, Pedro Reimunde. (2010) Hormona de crecimiento: acciones y aplicaciones preventivas y terapéuticas. Medicina Clínica 135:14, 665-670
CrossRef31
Evgenia Makrantonaki, Peter Schönknecht, Amir M. Hossini, Elmar Kaiser, Myrto-Maria Katsouli, James Adjaye, Johannes Schröder, Christos C. Zouboulis. (2010) Skin and brain age together: The role of hormones in the ageing process. Experimental Gerontology 45:10, 801-813
CrossRef32
Courtney Everts Mykytyn. 2010. A History of the Future: The Emergence of Contemporary Anti-Ageing Medicine. , 10-24.
CrossRef33
A. Larrayadieu. (2010) Effets de la stimulation de l’hormone de croissance chez les sujets âgés. Les cahiers de l'année gérontologique 2:3, 152-154
CrossRef34
R. Visvanathan, I. Chapman. (2010) Preventing sarcopaenia in older people. Maturitas 66:4, 383-388
CrossRef35
Courtney Everts Mykytyn. (2010) A history of the future: the emergence of contemporary anti-ageing medicine. Sociology of Health & Illness 32:2, 181-196
CrossRef36
Leanne M. Redman, Johannes D. Veldhuis, Jennifer Rood, Steven R. Smith, Donald Williamson, Eric Ravussin, . (2010) The effect of caloric restriction interventions on growth hormone secretion in nonobese men and women. Aging Cell 9:1, 32-39
CrossRef37
Ana Rakin, Danica Petrovic-Djergovic, Vera Todorovic, Irena Zivkovic, Dragoslava Djikic, Biljana Miljkovic, I. Jankovic, Mileva Micic. (2010) Somatostatin-14 induces different changes in the thymus of peripubertal and young adult rats. Acta veterinaria 60:4, 339-354
CrossRef38
Diane M. Watts-Roy. (2009) A protest vote? Users of anti-ageing medicine talk back. Health Sociology Review 18:4, 434-445
CrossRef39
Y. Boirie. (2009) Physiopathological mechanism of sarcopenia. The Journal of Nutrition, Health and Aging 13:8, 717-723
CrossRef40
Thomas T. Perls. (2009) Growth hormone and anabolic steroids: athletes are the tip of the iceberg. Drug Testing and Analysis 1:9â10, 419-425
CrossRef41
Y. Rolland, G. Abellan van Kan, A. Bénétos, H. Blain, M. Bonnefoy, P. Chassagne, C. Jeandel, M. Laroche, F. Nourhashémi, P. Orcel, F. Piette, C. Ribot, P. Ritz, C. Roux, J. Taillandier, F. Trémollières, G. Weryha, B. Vellas. (2009) Fragilité, ostéoporose et fracture du col du fémur: causes, conséquences et perspectives thérapeutiques. Les cahiers de l'année gérontologique 1:3, 172-187
CrossRef42
Emaad Abdel-Rahman, Jean L. Holley. (2009) A Review of the Effects of Growth Hormone Changes on Symptoms of Frailty in the Elderly with Chronic Kidney Disease. Seminars in Dialysis 22:5, 532-538
CrossRef43
Mitsuyoshi Sasaki, Ryo Okazaki, Daisuke Inoue, Michi Nakashima, Fuyuaki Ide, Hiroshi Nakaguchi, Shoko M. Yamada, Katsumi Hoya, Mineko Murakami, Akiko Mizutani, Hiroko Okinaga, Akira Matsuno. (2009) Preoperative Elevated Serum Growth Hormone is Preventive of Osteopenia in Postsurgical Patients With Pituitary Somatotroph Adenomas. The Endocrinologist 19:5, 208-210
CrossRef44
Joshua Boateng, Richard Kay, Lee Lancashire, Pamela Brown, Cristiana Velloso, Pierre Bouloux, Phil Teale, Jane Roberts, Robert Rees, Graham Ball, Stephen Harridge, Geoffrey Goldspink, Colin Creaser. (2009) A proteomic approach combining MS and bioinformatic analysis for the detection and identification of biomarkers of administration of exogenous human growth hormone in humans. PROTEOMICS - CLINICAL APPLICATIONS 3:8, 912-922
CrossRef45
Courtney Everts Mykytyn. (2009) Anti-Aging is not Necessarily Anti-Death: Bioethics and the Front Lines of Practice. Medicine Studies 1:3, 209-228
CrossRef46
Jung Min Kim, Seong-Yeong Kim, Eun-Young Jung, Song Hwan Bae, Hyung Joo Suh. (2009) Yeast hydrolysate induces longitudinal bone growth and growth hormone release in rats. Phytotherapy Research 23:5, 731-736
CrossRef47
Kurt J. Reyes, Homer J. LeMar. 2009. Growth Hormone and Insulin Use and Abuse. , 239-243.
CrossRef48
Erika T. Schwartz, Kent Holtorf. (2008) Hormones in Wellness and Disease Prevention: Common Practices, Current State of the Evidence, and Questions for the Future. Primary Care: Clinics in Office Practice 35:4, 669-705
CrossRef49
Valter D. Longo, Michael R. Lieber, Jan Vijg. (2008) Turning anti-ageing genes against cancer. Nature Reviews Molecular Cell Biology 9:11, 903-910
CrossRef50
Y. Rolland, S. Czerwinski, G. Abellan Kan, J. E. Morley, M. Cesari, G. Onder, J. Woo, R. Baumgartner, F. Pillard, Y. Boirie, W. M. C. Chumlea, B. Vellas. (2008) Sarcopenia: Its assessment, etiology, pathogenesis, consequences and future perspectives. The Journal of Nutrition Health and Aging 12:7, 433-450
CrossRef51
M. Cesari, M. Pahor. (2008) Target population for clinical trials on sarcopenia. The Journal of Nutrition Health and Aging 12:7, 470-478
CrossRef52
L. Groban, H. Jobe, M. Lin, T. Houle, D. A. Kitzman, W. Sonntag. (2008) Effects of Short-Term Treadmill Exercise Training or Growth Hormone Supplementation on Diastolic Function and Exercise Tolerance in Old Rats. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 63:9, 911-920
CrossRef53
Qun Li, Asli F. Ceylan-Isik, Ji Li, Jun Ren. (2008) Deficiency of Insulin-Like Growth Factor 1 Reduces Sensitivity to Aging-Associated Cardiomyocyte Dysfunction. Rejuvenation Research 11:4, 725-733
CrossRef54
Kate L. Gilbert, Keith A. Stokes, George M. Hall, Dylan Thompson. (2008) Growth hormone responses to 3 different exercise bouts in 18- to 25- and 40- to 50-year-old men. Applied Physiology, Nutrition, and Metabolism 33:4, 706-712
CrossRef55
C P Velloso. (2008) Regulation of muscle mass by growth hormone and IGF-I. British Journal of Pharmacology 154:3, 557-568
CrossRef56
Y. Rolland, G. Abellan Kan, A. Benetos, H. Blain, M. Bonnefoy, P. Chassagne, C. Jeandel, M. Laroche, F. Nourhashemi, P. Orcel, F. Piette, C. Ribot, P. Ritz, C. Roux, J. Taillandier, F. Tremollieres, G. Weryha, B. Vellas. (2008) Frailty, osteoporosis and hip fracture: Causes, consequences and therapeutic perspectives. The Journal of Nutrition Health and Aging 12:5, a319-a330
CrossRef57
D. Heutling, H. Lehnert. (2008) Hormontherapie und Anti-Aging. Der Internist 49:5, 570-580
CrossRef58
James J. Li, Haixia Wang, Jun Li, Fucheng Qu, Stephen G. Swartz, Andrés S. Hernández, Scott A. Biller, Jeffrey A. Robl, Joseph A. Tino, Dorothy Slusarchyk, Ramakrishna Seethala, Paul Sleph, Mujing Yan, Gary Grover, Neil Flynn, Brian J. Murphy, David Gordon. (2008) Tetrazole based amides as growth hormone secretagogues. Bioorganic & Medicinal Chemistry Letters 18:8, 2536-2539
CrossRef59
Hernando Rafael. (2008) Stem Cells. Journal of Neurosurgery 108:4, 841-842
CrossRef60
M. Barbieri, A. Gambardella, G. Paolisso, M. Varricchio. (2008) Metabolic aspects of the extreme longevity. Experimental Gerontology 43:2, 74-78
CrossRef61
A.M. Lichanska, M.J. Waters. (2008) New Insights into Growth Hormone Receptor Function and Clinical Implications. Hormone Research 69:3, 138-145
CrossRef62
RON G. ROSENFELD, PINCHAS COHEN. 2008. Disorders of Growth Hormone/Insulin-like Growth Factor Secretion and Action. , 254-334.
CrossRef63
B. Al-Qallaf, D. B. Das, D. Mori, Z. Cui. (2007) Modelling transdermal delivery of high molecular weight drugs from microneedle systems. Philosophical Transactions of the Royal Society A: Mathematical, Physical and Engineering Sciences 365:1861, 2951-2967
CrossRef64
Qun Li, Xiaoping Yang, Nair Sreejayan, Jun Ren. (2007) Insulin-Like Growth Factor I Deficiency Prolongs Survival and Antagonizes Paraquat–Induced Cardiomyocyte Dysfunction: Role of Oxidative Stress. Rejuvenation Research 10:4, 501-512
CrossRef65
Paul LaStayo, Paul McDonagh, Dani Lipovic, Phyllis Napoles, Amelia Bartholomew, Karyn Esser, Stan Lindstedt. (2007) Elderly Patients and High Force Resistance Exercise—A Descriptive Report. Journal of Geriatric Physical Therapy 30:3, 128-134
CrossRef66
Christopher R. McHenry. (2007) Presidential address: The illicit use of hormones for enhancement of athletic performance: A major threat to the integrity of organized athletic competition. Surgery 142:6, 785-792
CrossRef67
2007. Exercise and Protein Metabolism. , 23-106.
CrossRef68
Ho-Young Lee, Dae-Young Jung, Hye-Kyung Ha, Sam-Sik Kang, Ju-Sun Kim, Chung-Sook Kim. (2007) Induction of Growth Hormone Release by Glycyrrhizae Radix on Rat. Journal of Biochemistry and molecular biology 40:6, 979-985
CrossRef69
Santiago Rodriguez, Tom R. Gaunt, Ian N. M. Day. (2007) Molecular genetics of human growth hormone, insulin-like growth factors and their pathways in common disease. Human Genetics 122:1, 1-21
CrossRef70
Hernando Rafael. (2007) Low-Back Pain. Journal of Neurosurgery: Spine 7:1, 114-116
CrossRef71
Ariel L Barkan. (2007) Growth hormone as an anti-aging therapy—do the benefits outweigh the risks?. Nature Clinical Practice Endocrinology & Metabolism 3:7, 508-509
CrossRef72
A. V. Kulikov, L. V. Arkhipova, G. N. Smirnova, Yu. N. Korystov, V. V. Shaposhnikova, T. M. Tret’yak, D. A. Kulikov, L. M. Chailakhyan. (2007) May the rate of thymus age-related involution be reduced by grafting immunocompetent or neural tissues?. Doklady Biological Sciences 414:1, 185-186
CrossRef73
E. Tsiridis, Z. Gamie, P.G. Conaghan, P.V. Giannoudis. (2007) Biological options to enhance periprosthetic bone mass. Injury 38:6, 704-713
CrossRef74
Mark Sherlock, Andrew A. Toogood. (2007) Aging and the growth hormone/insulin like growth factor-I axis. Pituitary 10:2, 189-203
CrossRef75
Boguslawa Baranowska, Ewa Wolinska-Witort, Wojciech Bik, Agnieszka Baranowska-Bik, Lidia Martynska, Magdalena Chmielowska. (2007) Evaluation of neuroendocrine status in longevity. Neurobiology of Aging 28:5, 774-783
CrossRef76
Neal Spruce, Alan Titchenal. 2007. Other Individual Amino Acids. .
CrossRef77
Jonathan M. Labovitz, Kate Revill. (2007) Osteoporosis: Pathogenesis, New Therapies and Surgical Implications. Clinics in Podiatric Medicine and Surgery 24:2, 311-332
CrossRef78
Ralf Nass, Jennifer Park, Michael O. Thorner. (2007) Growth Hormone Supplementation in the Elderly. Endocrinology & Metabolism Clinics of North America 36:1, 233-245
CrossRef79
Derek LeRoith, Shoshana Yakar. (2007) Mechanisms of Disease: metabolic effects of growth hormone and insulin-like growth factor 1. Nature Clinical Practice Endocrinology & Metabolism 3:3, 302-310
CrossRef80
HS Chahal, WM Drake. (2007) The endocrine system and ageing. The Journal of Pathology 211:2, 173-180
CrossRef81
William J. Evans, Charles P. Lambert. (2007) Physiological Basis of Fatigue. American Journal of Physical Medicine & Rehabilitation 86:Supplement, S29-S46
CrossRef82
Sergio Giralt, Maureen Simmonds, Roy Smith. (2007) Measures of Morbidity: Functional Assessment and Cytokines. Biology of Blood and Marrow Transplantation 13, 98-102
CrossRef83
AJ Freemont, JA Hoyland. (2007) Morphology, mechanisms and pathology of musculoskeletal ageing. The Journal of Pathology 211:2, 252-259
CrossRef84
Fatih Tanriverdi, Murat Borlu, Hulusi Atmaca, Cagdas Atasavun Koc, Kursad Unluhizarci, Serap Utas, Fahrettin Kelestimur. (2006) Investigation of the skin characteristics in patients with severe GH deficiency and the effects of 6
months of GH replacement therapy: a randomized placebo controlled study. Clinical Endocrinology 65:5, 579-585
CrossRef85
Richard F Walker. (2006) On the evolution of anti-aging medicine. Clinical Interventions in Aging 1:3, 201-203
CrossRef86
Susan Kaweski. (2006) Anti-Aging Medicine: Part 3. Growth Hormone Replacement. Plastic and Reconstructive Surgery 118:1, 253-256
CrossRef87
B. A. Forshee. (2006) The aging brain: is function dependent on growth hormone/insulin-like growth factor-1 signaling?. AGE 28:2, 173-180
CrossRef88
Zvi Laron. (2006) Hormona de crecimiento y factor de crecimiento insulinoide tipo 1: ¿Benefician o perjudican el envejecimiento?. Revista Española de Geriatría y Gerontología 41:3, 147-149
CrossRef89
Kevin Short. 2006. Muscle Atrophy During Aging. , 305-335.
CrossRef90
Richard F Walker. (2006) Clinical Interventions in Aging : a forum for practitioners of evidence-based ?anti-aging medicine?. Clinical Interventions in Aging 1:1, 1-2
CrossRef91
Monica Girotra, Mishaela R Rubin, John P Bilezikian. (2006) Anabolic Agents for Osteoporosis. Treatments in Endocrinology 5:6, 347-358
CrossRef92
L. Groban, N. A. Pailes, C. D. L. Bennett, C. S. Carter, M. C. Chappell, D. W. Kitzman, W. E. Sonntag. (2006) Growth Hormone Replacement Attenuates Diastolic Dysfunction and Cardiac Angiotensin II Expression in Senescent Rats. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 61:1, 28-35
CrossRef93
Paul Carroll. 2005. Growth Hormone. , 347-368.
CrossRef94
Carmen Castillo, Mar Cruzado, Carmen Ariznavarreta, Pablo Gil-Loyzaga, Vicente Lahera, Victoria Cachofeiro, Jesús A. F. Tresguerres. (2005) Effect of Recombinant Human Growth Hormone Administration on Body Composition and Vascular Function and Structure in Old Male Wistar Rats. Biogerontology 6:5, 303-312
CrossRef95
Kevin Flurkey. 2005. Gerontology. .
CrossRef96
B.A. Dowling, A.J. Dart. (2005) Mechanical and functional properties of the equine superficial digital flexor tendon. The Veterinary Journal 170:2, 184-192
CrossRef97
P. H. Kann. (2005) Wachstumshormontherapie beim Erwachsenen. Der Internist 46:9, 1047-1052
CrossRef98
Diego Fernández-García, Guillermo Alonso, Manuel Muñoz-Torres. (2005) Tratamiento anabólico en la osteoporosis. Medicina Clínica 125:9, 341-345
CrossRef99
Erik J.J. Duschek, Louis J. Gooren, Coen Netelenbos. (2005) Comparison of effects of the rise in serum testosterone by raloxifene and oral testosterone on serum insulin-like growth factor-1 and insulin-like growth factor binding protein-3. Maturitas 51:3, 286-293
CrossRef100
James W. Moor, M. Iqbal J. Khan. (2005) Growth hormone abuse and bodybuilding as aetiological factors in the development of bilateral internal laryngocoeles. A case report. European Archives of Oto-Rhino-Laryngology 262:7, 570-572
CrossRef101
Maria L. Urso, Maria A. Fiatarone Singh, Wenjing Ding, William J. Evans, Arthur C. Cosmas, Thomas G. Manfredi. (2005) Exercise training effects on skeletal muscle plasticity and IGF-1 receptors in frail elders. AGE 27:2, 117-125
CrossRef102
William E. Sonntag, Melinda Ramsey, Christy S. Carter. (2005) Growth hormone and insulin-like growth factor-1 (IGF-1) and their influence on cognitive aging. Ageing Research Reviews 4:2, 195-212
CrossRef103
James J. Li, Haixia Wang, Fucheng Qu, Christa Musial, Joseph A. Tino, Jeffrey A. Robl, Dorothy Slusarchyk, Rajasree Golla, Ramakrishna Seethala, Kenneth Dickinson, Leah Giupponi, Gary Grover, Paul Sleph, Neil Flynn, Brian J. Murphy, David Gordon, Melissa Kung, Robert Stoffel. (2005) Tetrahydroisoquinoline 1-carboxamides as growth hormone secretagogues. Bioorganic & Medicinal Chemistry Letters 15:7, 1799-1802
CrossRef104
P. Quatresooz, T. Hermanns-Le, A. Ciccarelli, A. Beckers, G. E. Pierard. (2005) Tensegrity and type 1 dermal dendrocytes in acromegaly. European Journal of Clinical Investigation 35:2, 133-139
CrossRef105
Jan Vijg, Yousin Suh. (2005) Genetics of Longevity and Aging. Annual Review of Medicine 56:1, 193-212
CrossRef106
Mohamed S. Ahmed, Brittany Matsumura, Adrian Cristian. (2005) Age-related changes in muscles and joints. Physical Medicine and Rehabilitation Clinics of North America 16:1, 19-39
CrossRef107
Deborah R Cameron, Glenn D Braunstein. (2005) The Use of Dehydroepiandrosterone Therapy in Clinical Practice. Treatments in Endocrinology 4:2, 95-114
CrossRef108
C. Castillo, M. Cruzado C. Ariznavarreta, V. Lahera, V. Cachofeiro, P. Gil-Loyzaga, Jes
CrossRef109
Andrea Rinaldi. (2004) Hormone therapy for the ageing. EMBO reports 5:10, 938-941
CrossRef110
Paola Lorenzon, Elena Bandi, Francesca de Guarrini, Tiziana Pietrangelo, Ralf Schäfer, Margit Zweyer, Anton Wernig, Fabio Ruzzier. (2004) Ageing affects the differentiation potential of human myoblasts. Experimental Gerontology 39:10, 1545-1554
CrossRef111
R Nass, M.O Thorner. (2004) Life extension versus improving quality of life. Best Practice & Research Clinical Endocrinology & Metabolism 18:3, 381-391
CrossRef112
Yasir H Ibrahim, Douglas Yee. (2004) Insulin-like growth factor-I and cancer risk. Growth Hormone & IGF Research 14:4, 261-269
CrossRef113
Andrew R Hoffman, Gian Paolo Ceda. (2004) IGFs and aging: is there a rationale for hormone replacement therapy?. Growth Hormone & IGF Research 14:4, 296-300
CrossRef114
Elena Volpi, Reza Nazemi, Satoshi Fujita. (2004) Muscle tissue changes with aging. Current Opinion in Clinical Nutrition and Metabolic Care 7:4, 405-410
CrossRef115
Michael N. Pollak, Eva S. Schernhammer, Susan E. Hankinson. (2004) Insulin-like growth factors and neoplasia. Nature Reviews Cancer 4:7, 505-518
CrossRef116
S. M. Harman, M. R. Blackman. (2004) Hormones and Supplements: Do They Work?: Use of Growth Hormone for Prevention or Treatment of Effects of Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:7, B652-B658
CrossRef117
T. T. Perls. (2004) Anti-Aging Medicine: The Legal Issues: Anti-Aging Quackery: Human Growth Hormone and Tricks of the Trade--More Dangerous Than Ever. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:7, B682-B691
CrossRef118
Neal Spruce, C Alan Titchenal. 2004. Lysine. , 171-196.
CrossRef119
Ulla Feldt-Rasmussen, Patrick Wilton, Peter Jonsson. (2004) Aspects of growth hormone deficiency and replacement in elderly hypopituitary adults. Growth Hormone & IGF Research 14, 51-58
CrossRef120
Yok L. Kwong, Clarence C. K. Lam. (2004) Polycythemia in a Physician Secondary to Self-Administered Growth Hormone, Testosterone, and Dehydroepiandrosterone to Prevent Aging. Journal of the American Geriatrics Society 52:6, 1031-1032
CrossRef121
Mendel Jansen, Ian Darby, Thierry Abribat, Pascal Dubreuil, Eckhardt S Ferdinandi, John G Hardy. (2004) Pulmonary delivery of TH9507, a growth hormone releasing factor analogue, in the dog. International Journal of Pharmaceutics 276:1-2, 75-81
CrossRef122
J. E. Morley. (2004) Is the Hormonal Fountain of Youth Drying Up?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 59:5, M458-M460
CrossRef123
Kai Henrik Wiborg Lange. (2004) Fat metabolism in exercise - with special reference to training and growth hormone administration. Scandinavian Journal of Medicine and Science in Sports 14:2, 74-99
CrossRef124
Mark A. Bach, Kenneth Rockwood, Carl Zetterberg, Gorm Thamsborg, Réjean Hébert, Jean-Pierre Devogelaer, Jens Sandahl Christiansen, René Rizzoli, J.Lockwood Ochsner, Norman Beisaw, Oscar Gluck, Leisure Yu, Thomas Schwab, Jeanne Farrington, Alice M. Taylor, Jennifer Ng, Vivian Fuh, . (2004) The Effects of MK-0677, an Oral Growth Hormone Secretagogue, in Patients with Hip Fracture. Journal of the American Geriatrics Society 52:4, 516-523
CrossRef125
P. Szulc, M. O. Joly–Pharaboz, F. Marchand, P. D. Delmas. (2004) Insulin-Like Growth Factor I Is a Determinant of Hip Bone Mineral Density in Men Less Than 60 years of Age: MINOS Study. Calcified Tissue International 74:4, 322-329
CrossRef126
Peter Conrad, Deborah Potter. (2004) Human growth hormone and the temptations of biomedical enhancement. Sociology of Health and Illness 26:2, 184-215
CrossRef127
Jennifer L. Copeland. (2004) Anabolic Hormones in Aging Women: Effects of Supplementation vs. Physical Activity. Canadian Journal of Applied Physiology 29:1, 76-89
CrossRef128
B.A Kinney-Forshee, N.E Kinney, R.W Steger, A Bartke. (2004) Could a deficiency in growth hormone signaling be beneficial to the aging brain?. Physiology & Behavior 80:5, 589-594
CrossRef129
Richard F Walker, Barry B Bercu. (2004) Contemporary Therapies in Longevity. Evidence-Based Integrative Medicine 1:3, 217-222
CrossRef130
B. HAFEZ, E. S. E. HAFEZ. (2004) ANDROPAUSE: ENDOCRINOLOGY, ERECTILE DYSFUNCTION, AND PROSTATE PATHOPHYSIOLOGY. Systems Biology in Reproductive Medicine 50:2, 45-68
CrossRef131
Margareta Hedström, Maria Sääf, Eva Brosjö, Carolin Hurtig, Kerstin Sjöberg, Ann Wesslau, Nils Dalén. (2004) Positive effects of short-term growth hormone treatment on lean body mass and BMC after a hip fracture A double-blind placebo-controlled pilot study in 20 patients. Acta Orthopaedica 75:4, 394-401
CrossRef132
Nagi Kumar. (2004) Editorial. Evidence-Based Integrative Medicine 1:3, 167-168
CrossRef133
Andrew A Toogood. (2004) The Somatopause. Treatments in Endocrinology 3:4, 201-209
CrossRef134
Jan-Ove Johansson, Lena Wirén, Jan Oscarsson, Bengt-Åke Bengtsson, Gudmundur Johannsson. (2003) Growth hormone (GH) replacement in GH-deficient adults: a crossover trial comparing the effect on metabolic control, well-being and compliance of three injections per week versus daily injections. Growth Hormone & IGF Research 13:6, 306-315
CrossRef135
A.-L. Yeo, D. Levy, F.C. Martin, P. Sönksen, I. Sturgess, M.M. Wheeler, A. Young. (2003) Frailty and the biochemical effects of recombinant human growth hormone in women after surgery for hip fracture. Growth Hormone & IGF Research 13:6, 361-370
CrossRef136
Howard B. Cottam. 2003. Antiaging Agents. .
CrossRef137
Edward M Messing, Ian Thompson. (2003) Follow-up of conservatively managed prostate cancer. Urologic Clinics of North America 30:4, 687-702
CrossRef138
Gregory M. Fahy. (2003) Apparent Induction of Partial Thymic Regeneration in a Normal Human Subject: A Case Report. Journal of Anti-Aging Medicine 6:3, 219-227
CrossRef139
Andrzej Bartke. (2003) Is growth hormone deficiency a beneficial adaptation to aging? Evidence from experimental animals. Trends in Endocrinology & Metabolism 14:7, 340-344
CrossRef140
Gudmundur Johannsson, Jarl Ahlmén. (2003) End-stage renal disease: endocrine aspects of treatment. Growth Hormone & IGF Research 13, S94-S101
CrossRef141
Sala Horowitz. (2003) Human Growth Hormone and Antiaging Medicine: Research and Views on Supplementation. Alternative and Complementary Therapies 9:4, 163-169
CrossRef142
L. Kappeler, D. Gourdji, P. Zizzari, M.-T. Bluet-Pajot, J. Epelbaum. (2003) Age-Associated Changes in Hypothalamic and Pituitary Neuroendocrine Gene Expression in the Rat. Journal of Neuroendocrinology 15:6, 592-601
CrossRef143
E.M Dennison, P.C Hindmarsh, S Kellingray, C.H.D Fall, C Cooper. (2003) Growth hormone predicts bone density in elderly women. Bone 32:4, 434-440
CrossRef144
Kerstin Landin-Wilhelmsen, Anders Nilsson, Ingvar Bosaeus, Bengt-Åke Bengtsson. (2003) Growth Hormone Increases Bone Mineral Content in Postmenopausal Osteoporosis: A Randomized Placebo-Controlled Trial. Journal of Bone and Mineral Research 18:3, 393-405
CrossRef145
Mishaela R Rubin, John P Bilezikian. (2003) New anabolic therapies in osteoporosis. Endocrinology & Metabolism Clinics of North America 32:1, 285-307
CrossRef146
Clifford J Rosen, Christian Wüster. (2003) Growth Hormone Rising: Did We Quit Too Quickly?. Journal of Bone and Mineral Research 18:3, 406-409
CrossRef147
Vladimir N. Anisimov. (2003) The relationship between aging and carcinogenesis: a critical appraisal. Critical Reviews in Oncology/Hematology 45:3, 277-304
CrossRef148
Vance, Mary Lee, . (2003) Can Growth Hormone Prevent Aging?. New England Journal of Medicine 348:9, 779-780
Full Text149
Drazen, Jeffrey M., . (2003) Inappropriate Advertising of Dietary Supplements. New England Journal of Medicine 348:9, 777-778
Full Text150
Stephen D. Hursting, Jackie A. Lavigne, David Berrigan, Susan N. Perkins, J. Carl Barrett. (2003) Calorie Restriction, Aging, and Cancer Prevention: Mechanisms of Action and Applicability to Humans*. Annual Review of Medicine 54:1, 131-152
CrossRef151
J. Dorrens, M. J. Rennie. (2003) Effects of ageing and human whole body and muscle protein turnover. Scandinavian Journal of Medicine and Science in Sports 13:1, 26-33
CrossRef152
David E. Cummings, George R. Merriam. (2003) Growth Hormone Therapy in Adults. Annual Review of Medicine 54:1, 513-533
CrossRef153
Andrew J. Weissberger, Anastasios D. Anastasiadis, Ian Sturgess, Finbarr C. Martin, Michael A. Smith, Peter H. Sonksen. (2003) Recombinant human growth hormone treatment in elderly patients undergoing elective total hip replacement. Clinical Endocrinology 58:1, 99-107
CrossRef154
Mark S Juhn. (2003) Popular Sports Supplements and Ergogenic Aids. Sports Medicine 33:12, 921-939
CrossRef155
Isabel F. Tresguerres, Celia Clemente, Manuel Donado, Luis Gomez-Pellico, Luis Blanco, Miguel Angel Alobera, Jesus A. F. Tresguerres. (2002) Local administration of growth hormone enhances periimplant bone reaction in an osteoporotic rabbit model. An histologic, histomorphometric and densitometric study. Clinical Oral Implants Research 13:6, 631-636
CrossRef156
Alberto Farah. (2002) A Comparison of Growth Hormone Administration and Exercise in the Elderly. Journal of Anti-Aging Medicine 5:4, 355-367
CrossRef157
M Bonnefoy, M.C Patricot, J.R Lacour, A Rahmani, S Berthouze, T Kostka. (2002) Relations entre l’activité physique, la fonction musculaire et les concentrations en IGF-1, testostérone et DHEAS lors de l’avancée en âge. La Revue de Médecine Interne 23:10, 819-827
CrossRef158
A. Fisher, J. E. Morley. (2002) Editorial: Antiaging Medicine: The Good, the Bad, and the Ugly. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:10, M636-M639
CrossRef159
E. J. Metter, L. A. Talbot, M. Schrager, R. Conwit. (2002) Skeletal Muscle Strength as a Predictor of All-Cause Mortality in Healthy Men. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:10, B359-B365
CrossRef160
D Chaouat. (2002) Les nouveaux traitements ostéoformateurs de l'ostéoporose. La Revue de Médecine Interne 23:9, 759-767
CrossRef161
Barry B. Bercu, Richard F. Walker. (2002) Relative Values of Recombinant Growth Hormone and Growth Hormone Secretagogues in Clinical Practice. The Endocrinologist 12:5, 433-444
CrossRef162
R. F. Walker. (2002) Anti-Aging Medicine: Collecting Data or Collecting Fees?. Journal of Anti-Aging Medicine 5:3, 243-246
CrossRef163
R. N. Butler, M. Fossel, S. M. Harman, C. B. Heward, S. J. Olshansky, T. T. Perls, D. J. Rothman, S. M. Rothman, H. R. Warner, M. D. West, W. E. Wright. (2002) Is There an Antiaging Medicine?. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:9, B333-B338
CrossRef164
S. J. Olshansky, L. Hayflick, B. A. Carnes. (2002) Position Statement on Human Aging. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:8, B292-B297
CrossRef165
Mishaela R. Rubin, John P. Bilezikian. (2002) New anabolic therapies in osteoporosis. Current Opinion in Rheumatology 14:4, 433-440
CrossRef166
H. M. Fillit, R. N. Butler, A. W. O'Connell, M. S. Albert, J. E. Birren, C. W. Cotman, W. T. Greenough, P. E. Gold, A. F. Kramer, L. H. Kuller, T. T. Perls, B. G. Sahagan, T. Tully. (2002) Achieving and Maintaining Cognitive Vitality With Aging. Mayo Clinic Proceedings 77:7, 681-696
CrossRef167
R Nass, M.O Thorner. (2002) Impact of the GH–cortisol ratio on the age-dependent changes in body composition. Growth Hormone & IGF Research 12:3, 147-161
CrossRef168
Christy S. Carter, Melinda M. Ramsey, William E. Sonntag. (2002) A critical analysis of the role of growth hormone and IGF-1 in aging and lifespan. Trends in Genetics 18:6, 295-301
CrossRef169
Guiyun Wang, Heung-Man Lee, Ella Englander, George H Greeley. (2002) Ghrelin—not just another stomach hormone. Regulatory Peptides 105:2, 75-81
CrossRef170
C. S. Carter, M. M. Ramsey, R. L. Ingram, A. B. Cashion, W. T. Cefalu, Z.Q. Wang, W. E. Sonntag. (2002) Models of Growth Hormone and IGF-1 Deficiency: Applications to Studies of Aging Processes and Life-Span Determination. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:5, B177-B188
CrossRef171
J. L. Copeland, L. A. Consitt, M. S. Tremblay. (2002) Hormonal Responses to Endurance and Resistance Exercise in Females Aged 19-69 Years. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:4, B158-B165
CrossRef172
Richard A. Miller. (2002) Extending Life: Scientific Prospects and Political Obstacles. The Milbank Quarterly 80:1, 155-174
CrossRef173
Richard F. Walker. (2002) Assessing Safety and Efficacy of Growth Hormone Replacement in Aging by Community Physicians. Journal of Anti-Aging Medicine 5:1, 41-55
CrossRef174
Helen Simpson, Richard Savine, Peter Sönksen, Bengt-Åke Bengtsson, Lena Carlsson, Jens Sandahl Christiansen, David Clemmons, Pinchus Cohen. Raymond Hintz, Ken Ho, Primus Mullis, Iain Robinson, Christian Strasburger, Toshiaka Tanaka, Michael Thorner. (2002) Growth hormone replacement therapy for adults: Into the new millennium. Growth Hormone & IGF Research 12:1, 1-33
CrossRef175
Amber R Buz'Zard, Qiaoling Peng, Benjamin H.S Lau. (2002) Kyolic® and Pycnogenol® increase human growth hormone secretion in genetically-engineered keratinocytes. Growth Hormone & IGF Research 12:1, 34-40
CrossRef176
Mohamad H. Horani, Arshag D. Mooradian. (2002) Management of Obesity in the Elderly. Treatments in Endocrinology 1:6, 387-398
CrossRef177
Laurie Wideman, Judy Y. Weltman, Mark L. Hartman, Johannes D. Veldhuis, Arthur Weltman. (2002) Growth Hormone Release During Acute and Chronic Aerobic and Resistance Exercise. Sports Medicine 32:15, 987-1004
CrossRef178
C. Christmas, K. G. O'Connor, S. M. Harman, J. D. Tobin, T. Munzer, M. F. Bellantoni, C. St. Clair, K. M. Pabst, J. D. Sorkin, M. R. Blackman. (2002) Growth Hormone and Sex Steroid Effects on Bone Metabolism and Bone Mineral Density in Healthy Aged Women and Men. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 57:1, M12-M18
CrossRef179
Andrezej Bartke. (2001) A Word of Caution: Can Growth Hormone Accelerate Aging?. Journal of Anti-Aging Medicine 4:4, 301-309
CrossRef180
OMID KHORRAM. (2001) Use of Growth Hormone and Growth Hormone Secretagogues in Aging: Help or Harm. Clinical Obstetrics and Gynecology 44:4, 893-901
CrossRef181
William E. Sonntag, Judy K. Brunso-Bechtold, David R. Riddle. (2001) Age-Related Decreases in Growth Hormone and Insulin-Like Growth Factor (IGF)–1: Implications for Brain Aging. Journal of Anti-Aging Medicine 4:4, 311-329
CrossRef182
George R. Merriam, Suzanne Barsness, David Buchner, Monica Kletke, Lawrence H. Larsen, Karen E. Moe, Robert S. Schwartz, Michael V. Vitiello. (2001) Growth Hormone Releasing Hormone Treatment in Normal Aging. Journal of Anti-Aging Medicine 4:4, 331-343
CrossRef183
David Leonardi, Alan P. Mintz, Anton Dotson, Jhoanna Mukai. (2001) Hormone Modulation, Low Glycemic Nutrition, and Exercise Instruction: Effects on Disease Risk and Quality of Life. Journal of Anti-Aging Medicine 4:4, 357-371
CrossRef184
E. Ghigo, E. Arvat, F. Broglio, M. Papotti, G. Muccioli, R. Deghenghi. (2001) Natural and Synthetic Growth Hormone Secretagogues: Endocrine and Nonendocrine Activities Suggesting Their Potential Usefulness as Anti-Aging Drug Interventions. Journal of Anti-Aging Medicine 4:4, 345-356
CrossRef185
Richard F. Walker, Barry B. Bercu. (2001) Issues Regarding the Routine and Long-Term Use of Growth Hormone in Anti-Aging Medicine. Journal of Anti-Aging Medicine 4:4, 279-300
CrossRef186
Cemal Posaci, Sabahattin Altunyurt, Huray Islekel, Ata Onvural. (2001) Effects of HRT on serum levels of IGF-I in postmenopausal women. Maturitas 40:1, 69-74
CrossRef187
N.B. Andersen, K. Malmlöf, P.B. Johansen, T.T. Andreassen, G. Ørtoft, H. Oxlund. (2001) The growth hormone secretagogue ipamorelin counteracts glucocorticoid-induced decrease in bone formation of adult rats. Growth Hormone & IGF Research 11:5, 266-272
CrossRef188
Julie A. Mattison, George S. Roth, Donald K. Ingram, Mark A. Lane. (2001) Endocrine Effects of Dietary Restriction and Aging: The National Institute on Aging Study. Journal of Anti-Aging Medicine 4:3, 215-223
CrossRef189
Hiroshi Kaji, Toshitsugu Sugimoto, Daiki Nakaoka, Yasuhiko Okimura, Hidesuke Kaji, Hiromi Abe, Kazuo Chihara. (2001) Bone metabolism and body composition in Japanese patients with active acromegaly. Clinical Endocrinology 55:2, 175-181
CrossRef190
A. Bartke, K. Coschigano, J. Kopchick, V. Chandrashekar, J. Mattison, B. Kinney, S. Hauck. (2001) Genes That Prolong Life: Relationships of Growth Hormone and Growth to Aging and Life Span. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:8, B340-B349
CrossRef191
A. S. Khan, C. D. Lynch, D. C. Sane, M. C. Willingham, W. E. Sonntag. (2001) Growth Hormone Increases Regional Coronary Blood Flow and Capillary Density in Aged Rats. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:8, B364-B371
CrossRef192
Kai Henrik Wiborg Lange, Fredrik Isaksson, Michael Hojby Rasmussen, Anders Juul, Jens Bulow, Michael Kjaer. (2001) GH administration and discontinuation in healthy elderly men: effects on body composition, GH-related serum markers, resting heart rate and resting oxygen uptake. Clinical Endocrinology 55:1, 77-86
CrossRef193
V Anisimov. (2001) Life span extension and cancer risk: myths and reality. Experimental Gerontology 36:7, 1101-1136
CrossRef194
James V. Hennessey, Joseph A. Chromiak, Shirley DellaVentura, Steven E. Reinert, Jacqueline Puhl, Douglas P. Kiel, Clifford J. Rosen, Herman Vandenburgh, David B. MacLean. (2001) Growth Hormone Administration and Exercise Effects on Muscle Fiber Type and Diameter in Moderately Frail Older People. Journal of the American Geriatrics Society 49:7, 852-858
CrossRef195
Holly Brown-Borg, W. Thomas Johnson, Sharlene Rakoczy, Mark Romanick. (2001) Mitochondrial oxidant generation and oxidative damage in Ames dwarf and GH transgenic mice. AGE 24:3, 85-96
CrossRef196
Paul J. Jenkins. (2001) Growth hormone and exercise: Physiology, use and abuse. Growth Hormone & IGF Research 11, S71-S77
CrossRef197
D Gems. (2001) Insulin/IGF signalling and ageing: seeing the bigger picture. Current Opinion in Genetics & Development 11:3, 287-292
CrossRef198
Gordon L. Jensen, Melissa McGee, Jeff Binkley. (2001) NUTRITION IN THE ELDERLY. Gastroenterology Clinics of North America 30:2, 313-334
CrossRef199
B.A Kinney, K.T Coschigano, J.J Kopchick, R.W Steger, A Bartke. (2001) Evidence that age-induced decline in memory retention is delayed in growth hormone resistant GH-R-KO (Laron) mice. Physiology & Behavior 72:5, 653-660
CrossRef200
S. J. Hauck, A. Bartke. (2001) Free Radical Defenses in the Liver and Kidney of Human Growth Hormone Transgenic Mice: Possible Mechanisms of Early Mortality. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:4, B153-B162
CrossRef201
M.-M. G. Wilson. (2001) Guest Editorial: Bitter-Sweet Memories: Truth and Fiction. The Journals of Gerontology Series A: Biological Sciences and Medical Sciences 56:4, M196-M199
CrossRef202
Shigeru Okada, John J Kopchick. (2001) Biological effects of growth hormone and its antagonist. Trends in Molecular Medicine 7:3, 126-132
CrossRef203
Zhi-ping Zong, Shinobu Matsui, Ai-li Li, Nobuo Yamaguchi, Shogo Katsuda, Mitsuru Hayase, Michael LX Fu. (2001) Growth hormone interferes with the progression of myocarditis in rats. European Journal of Pharmacology 415:1, 51-60
CrossRef204
Clifford J. Rosen, Paula J. Rackoff. (2001) Emerging Anabolic Treatments for Osteoporosis. Rheumatic Disease Clinics of North America 27:1, 215-233
CrossRef205
Igor D. Grachev, A. Vania Apkarian. (2001) Aging alters regional multichemical profile of the human brain: an in vivo 1 H-MRS study of young versus middle-aged subjects. Journal of Neurochemistry 76:2, 582-593
CrossRef206
Eckhard Leifke, Vitali Gorenoi, Christian Wichers, Alexander von zur Muhlen, Erico von Buren, Georg Brabant. (2000) Age-related changes of serum sex hormones, insulin-like growth factor-1 and sex-hormone binding globulin levels in men: cross-sectional data from a healthy male cohort. Clinical Endocrinology 53:6, 689-695
CrossRef207
M Brian Wallace. 2000. Overview of Anabolic/Androgenic Hormones and Strength. , 133-156.
CrossRef208
G. Paolisso, M. Barbieri, M. Bonafe, C. Franceschi. (2000) Metabolic age modelling: the lesson from centenarians. European Journal of Clinical Investigation 30:10, 888-894
CrossRef209
Lars Larsson, Bhagavathi Ramamurthy. (2000) Aging-Related Changes in Skeletal Muscle. Drugs & Aging 17:4, 303-316
CrossRef210
Andrzej Bartke, Holly Brown-Borg, Beth Kinney, Julie Mattison, Chris Wright, Steven Hauck, Karen Coschigano, John Kopchick. (2000) Growth hormone and aging. AGE 23:4, 219-225
CrossRef211
H Janssens. (2000) Endocrinological aspects of aging in men: is hormone replacement of benefit?. European Journal of Obstetrics & Gynecology and Reproductive Biology 92:1, 7-12
CrossRef212
John P. Monson, Roger Abs, Bengt-Åke Bengtsson, Helge Bennmarker, Ulla Feldt-Rasmussen, Elizabeth Hernberg-Ståhl, Marja Thorén, Björn Westberg, Patrick Wilton, Christian Wüster. (2000) Growth hormone deficiency and replacement in elderly hypopituitary adults. Clinical Endocrinology 53:3, 281-289
CrossRef213
Wolfgang K
CrossRef214
Melissa McGee, Gordon L. Jensen. (2000) Nutrition in the Elderly. Journal of Clinical Gastroenterology 30:4, 372-380
CrossRef215
ANNEWIEKE W. van den BELD, STEVEN W.J. LAMBERTS. (2000) Endocrine Determinants of Successful Aging in the Male. Journal of Anti-Aging Medicine 3:2, 159-167
CrossRef216
C La Vecchia, A Decarli, J Peto, F Levi, F Tomei, E Negri. (2000) An age, period and cohort analysis of pleural cancer mortality in Europe. European Journal of Cancer Prevention 9:3, 179-184
CrossRef217
Laurel A. Habel, Stephen K. Van Den Eeden, Gary D. Friedman. (2000) Body size, age at shaving initiation, and prostate cancer in a large, multiracial cohort. The Prostate 43:2, 136-143
CrossRef218
Igor D. Grachev, A.Vania Apkarian. (2000) Chemical Heterogeneity of the Living Human Brain: A Proton MR Spectroscopy Study on the Effects of Sex, Age, and Brain Region. NeuroImage 11:5, 554-563
CrossRef219
Gaye Cunnane, Nancy E. Lane. (2000) STEROID–INDUCED OSTEOPOROSIS IN SYSTEMIC LUPUS ERYTHEMATOSUS. Rheumatic Disease Clinics of North America 26:2, 311-329
CrossRef220
G. Johannsson, J. Svensson, B.-Å. Bengtsson. (2000) Growth hormone and ageing. Growth Hormone & IGF Research 10, S25-S30
CrossRef221
C.A. Lissett, S.M. Shalet. (2000) Effects of growth hormone on boneand muscle. Growth Hormone & IGF Research 10, S95-S101
CrossRef222
Sophia Lal, David W. Hart, David N. Herndon. (2000) Challenges of growth hormone therapy: pros. Current Opinion in Clinical Nutrition and Metabolic Care 3:2, 135-138
CrossRef223
Holly M. Brown–Borg, Sharlene G. Rakoczy. (2000) Catalase expression in delayed and premature aging mouse models
. Experimental Gerontology 35:2, 199-212
CrossRef224
M.Louay Omran, John E Morley. (2000) Assessment of protein energy malnutrition in older persons, part II: laboratory evaluation. Nutrition 16:2, 131-140
CrossRef225
SAMUEL S.C. YEN. (2000) Adrenal Andropause and Aging. Journal of Anti-Aging Medicine 3:3, 315-328
CrossRef226
Annewieke W. van den Beld, Steven W.J. Lamberts. (2000) The male climacterium: Clinical signs and symptoms of a changing endocrine environment. The Prostate 45:S10, 2-8
CrossRef227
Toshitsugu Sugimoto, Daiki Nakaoka, Masamichi Nasu, Michiko Kanzawa, Takeshi Sugishita, Kazuo Chihara. (1999) Effect of recombinant human growth hormone in elderly osteoporotic women. Clinical Endocrinology 51:6, 715-724
CrossRef228
Martin Hermann, Peter Berger. (1999) Hormone replacement in the aging male?
CrossRef229
Barbara Brewitt, James Hughes, Elizabeth A. Welsh, Robert Jackson. (1999) Three Double-Blind Placebo-Controlled Studies. Alternative and Complementary Therapies 5:6, 373-385
CrossRef230
Paul M. Arnold, Jianxin Y. Ma, Bruce A. Citron, Barry W. Festoff. (1999) Insulin-like Growth Factor Binding Proteins in Cerebrospinal Fluid during Human Development and Aging. Biochemical and Biophysical Research Communications 264:3, 652-656
CrossRef231
Kieran G. O'Connor, S.Mitchell Harman, Thomas E. Stevens, Jocelyn J. Jayme, Michele F. Bellantoni, M.Janette Busby-Whitehead, Colleen Christmas, Thomas Münzer, Jordan D. Tobin, Tracey A. Roy, Ernest Cottrell, Carol St. Clair, Katherine M. Pabst, Marc R. Blackman. (1999) Interrelationship of spontaneous growth hormone axis activity, body fat, and serum lipids is healthy elderly women and men. Metabolism 48:11, 1424-1431
CrossRef232
John J. Kopchick, Linda L. Bellush, Karen T. Coschigano. (1999) TRANSGENIC MODELS OF GROWTH HORMONE ACTION. Annual Review of Nutrition 19:1, 437-461
CrossRef233
M. G. Murphy, M. A. Bach, D. Plotkin, J. Bolognese, J. Ng, D. Krupa, K. Cerchio, B. J. Gertz. (1999) Oral Administration of the Growth Hormone Secretagogue MK-677 Increases Markers of Bone Turnover in Healthy and Functionally Impaired Elderly Adults. Journal of Bone and Mineral Research 14:7, 1182-1188
CrossRef234
Rachelle Bross, Tom Storer, Shalender Bhasin. (1999) Aging and Muscle Loss. Trends in Endocrinology & Metabolism 10:5, 194-198
CrossRef235
Murray, Skillicorn, Howell, Lissett, Rahim, Shalet. (1999) Dose titration and patient selection increases the efficacy of GH replacement in severely GH deficient adults. Clinical Endocrinology 50:6, 749-757
CrossRef236
Katia Mahlbacher, Anita Sicuro, Hans Gerber, Henry N. Hulter, Reto Krapf. (1999) Growth hormone corrects acidosis-induced renal nitrogen wasting and renal phosphate depletion and attenuates renal magnesium wasting in humans. Metabolism 48:6, 763-770
CrossRef237
Paul J. Jenkins. (1999) Growth hormone and exercise. Clinical Endocrinology 50:6, 683-689
CrossRef238
Meng-Hsin Chen, Patrick P. Pollard, Arthur A. Patchett, Kang Cheng, Liente Wei, Wanda W.-S. Chan, Bridget Butler, Thomas M. Jacks, Roy G. Smith. (1999) Synthesis and biological activities of spiroheterocyclic growth hormone secretagogues. Bioorganic & Medicinal Chemistry Letters 9:9, 1261-1266
CrossRef239
Clifford J Rosen, Michael Pollak. (1999) Circulating IGF-I: New Perspectives for a New Century. Trends in Endocrinology & Metabolism 10:4, 136-141
CrossRef240
J. Svensson. (1999) Growth hormone secretagogues astherapeutic agents. Growth Hormone & IGF Research 9, 107-109
CrossRef241
G LUISETTO, M ZACCARIA, S CESTARO, V CAMOZZI, F ANGELINI, M MOISE. (1999) Effect of growth hormone replacement therapy on bone mass, bone metabolism, and body composition in adult patients with growth hormone deficiency. Current Therapeutic Research 60:4, 237-249
CrossRef242
Antonio Cano, Camil Castelo-Branco, Juan J Tarı́n. (1999) Effect of menopause and different combined estradiol-progestin regimens on basal and growth hormone-releasing hormone–stimulated serum growth hormone, insulin-like growth factor-1, insulin-like growth factor binding protein (IGFBP)-1, and IGFBP-3 levels. Fertility and Sterility 71:2, 261-267
CrossRef243
Brian Steinke, Avinash G. Patwardhan, Robert M. Havey, Donna King. (1999) Human Growth Hormone Transgene Expression Increases the Biomechanical Structural Properties of Mouse Vertebrae. Spine 24:1, 1-4
CrossRef244
F.Brad Johnson, David A Sinclair, Leonard Guarente. (1999) Molecular Biology of Aging. Cell 96:2, 291-302
CrossRef245
A. G. Nugent, K. K. Y. Ho. (1998) Growth hormone-a panacea for aging?. Australian and New Zealand Journal of Medicine 28:6, 761-764
CrossRef246
Emanuela Arvat, Gianpaolo Ceda, Josefina Ramunni, Fabio Lanfranco, Gianluca Aimaretti, Laura Gianotti, Fabio Broglio, Ezio Ghigo. (1998) The IGF-I response to very low rhGH doses is preserved in human ageing. Clinical Endocrinology 49:6, 757-763
CrossRef247
Samuel S.C Yen, Gail A Laughlin. (1998) Aging and the adrenal cortex. Experimental Gerontology 33:7-8, 897-910
CrossRef248
A Bartke, H.M Brown-Borg, A.M Bode, J Carlson, W.S Hunter, R.T Bronson. (1998) Does growth hormone prevent or accelerate aging?. Experimental Gerontology 33:7-8, 675-687
CrossRef249
Stephen B. Trippel. (1998) Potential Role of Insulinlike Growth Factors in Fracture Healing. Clinical Orthopaedics and Related Research 355S, S301-S313
CrossRef250
A. J. Morales, R. H Haubrich, J. Y. Hwang, H Asakura, S. S. C Yen. (1998) The effect of six months treatment with a 100 mg daily dose of dehydroepiandrosterone (DHEA) on circulating sex steroids, body composition and muscle strength in age-advanced men and women. Clinical Endocrinology 49:4, 421-432
CrossRef251
N. Rousseau, P. Brazeau, H. Lapierre, T. Abribat. (1998) Effect of aging on growth hormone-induced insulin-like growth factor-I secretion from cultured rat chondrocytes. Growth Hormone & IGF Research 8:5, 403-409
CrossRef252
D Collins, A Woods, R Herd, G Blake, I Fogelman, M Wheeler, R Swaminathan. (1998) Insulin-like Growth Factor-I and Bone Mineral Density. Bone 23:1, 13-16
CrossRef253
J. Svensson, C. Ohlsson, J.-O. Jansson, G. Murphy, D. Wyss, D. Krupa, K. Cerchio, W. Polvino, B. Gertz, D. Baylink, S. Mohan, B.-Å. Bengtsson. (1998) Treatment with the Oral Growth Hormone Secretagogue MK-677 Increases Markers of Bone Formation and Bone Resorption in Obese Young Males. Journal of Bone and Mineral Research 13:7, 1158-1166
CrossRef254
N Tritos. (1998) Recombinant human growth hormone: old and novel uses. The American Journal of Medicine 105:1, 44-57
CrossRef255
Willy Hänggi, Kurt Lippuner, Philippe Jaeger, Martin H. Birkhäuser, Fritz F. Horber. (1998) Differential impact of conventional oral or transdermal hormone replacement therapy or tibolone on body composition in postmenopausal women. Clinical Endocrinology 48:6, 691-699
CrossRef256
Stephen Welle. (1998) Growth hormone and insulin-like growth factor-I as anabolic agents. Current Opinion in Clinical Nutrition and Metabolic Care 1:3, 257-262
CrossRef257
Andrew A. Toogood, Jenny Jones, Paul A. O'Neill, Michael O. Thorner, Stephen M. Shalet. (1998) The diagnosis of severe growth hormone deficiency in elderly patients with hypothalamic-pituitary disease. Clinical Endocrinology 48:5, 569-576
CrossRef258
AJ DART, M. STRONG, RJ ROSE, DR HODGSON. (1998) Effects of two large doses of equine recombinant growth hormone on clinical, haematological and serum biochemical variables in adult horses. Australian Veterinary Journal 76:5, 339-342
CrossRef259
Janssen, Stolk, Pols, Grobbee, de Jong, Lamberts. (1998) Serum free IGF-I, total IGF-I, IGFBP-1 and IGFBP-3 levels in an elderly population: relation to age and sex steroid levels. Clinical Endocrinology 48:4, 471-478
CrossRef260
JL Schlienger, B Goichot. (1998) Hormone de croissance : potion magique?. La Revue de Médecine Interne 19:4, 279-285
CrossRef261
Robert Marcus, Andrew R. Hoffman. (1998) GROWTH HORMONE AS THERAPY FOR OLDER MEN AND WOMEN. Annual Review of Pharmacology and Toxicology 38:1, 45-61
CrossRef262
C. Wüster, U. Härle, U. Rehn, C. Müller, K. Knauf, D. Köppler, C. Schwabe, R. Ziegler. (1998) Benefits of growth hormone treatment on bone metabolism, bone density and bone strength in growth hormone deficiency and osteoporosis. Growth Hormone & IGF Research 8, 87-94
CrossRef263
V.L. Fuh, M.A. Bach. (1998) Growth hormone secretagogues:mechanism of action and use in aging. Growth Hormone & IGF Research 8:1, 13-20
CrossRef264
Bernard Beaufrere, Yves Boirie. (1998) Aging and protein metabolism. Current Opinion in Clinical Nutrition and Metabolic Care 1:1, 85-89
CrossRef265
Franco Camanni, Ezio Ghigo, Emanuela Arvat. (1998) Growth Hormone-Releasing Peptides and Their Analogs. Frontiers in Neuroendocrinology 19:1, 47-72
CrossRef266
Ezio Ghigo, Emanuela Arvat, Franco Camanni. (1998) Orally active growth hormone secretagogues: state of the art and clinical perspectives. Annals of Medicine 30:2, 159-168
CrossRef267
JASON WOLFE. (1998) Growth Hormone: A Physiological Fountain of Youth?. Journal of Anti-Aging Medicine 1:1, 9-25
CrossRef268
William B. Ershler, S.Mitchell Harman, Evan T. Keller. (1997) Immunologic aspects of osteoporosis. Developmental & Comparative Immunology 21:6, 487-499
CrossRef269
William B. Ershler, Dan L. Longo. (1997) The biology of aging. Cancer 80:7, 1284-1293
CrossRef270
Alfredo Scillitani, Iacopo Chiodini, Vincenzo Carnevale, Giuseppe M. Giannatempo, Vincenzo Frusciante, Massimo Villella, Mauro Pileri, Giuseppe Guglielmi, Anna Di Giorgio, Sergio Modoni, Saverio Fusilli, Alfredo Di Cerbo, Antonio Liuzzi. (1997) Skeletal Involvement in Female Acromegalic Subjects: The Effects of Growth Hormone Excess in Amenorrheal and Menstruating Patients. Journal of Bone and Mineral Research 12:10, 1729-1736
CrossRef271
Siu T. Ng, Jian Zhou, Oluyemisi O. Adesanya, Jie Wang, Derek Leroith, Carolyn A. Bondy. (1997) Growth hormone treatment induces mammary gland hyperplasia in aging primates. Nature Medicine 3:10, 1141-1144
CrossRef272
Andrew R. Hoffman, Steven A. Lieberman, Gail Butterfield, Janice Thompson, Raymond L. Hintz, Gian Paolo Ceda, Robert Marcus. (1997) Functional consequences of the somatopause and its treatment. Endocrine 7:1, 73-76
CrossRef273
Robert Marcus. (1997) Skeletal effects of growth hormone and IGF-I in adults. Endocrine 7:1, 53-55
CrossRef274
Stephen E. Borst, David T. Lowenthal. (1997) Role of IGF-I in muscular atrophy of aging. Endocrine 7:1, 61-63
CrossRef275
Richard L. Atkinson. (1997) USE OF DRUGS IN THE TREATMENT OF OBESITY. Annual Review of Nutrition 17:1, 383-403
CrossRef276
Michel A. Hofman. (1997) Lifespan changes in the human hypothalamus. Experimental Gerontology 32:4-5, 559-575
CrossRef277
Annamaria Luca, Sabata Pierno, Daniela Cocchi, Diana Conte Camerino. (1997) Effects of chronic growth hormone treatment in aged rats on the biophysical and pharmacological properties of skeletal muscle chloride channels. British Journal of Pharmacology 121:3, 369-374
CrossRef278
Cristina P De la Cruz, Elisa Revilla, Jose A Rodrı́guez-Gómez, Marı́a Luisa Vizuete, Josefina Cano, Alberto Machado. (1997) (−)-Deprenyl treatment restores serum insulin-like growth factor-I (IGF-I) levels in aged rats to young rat level. European Journal of Pharmacology 327:2-3, 215-220
CrossRef279
James R. Tata, Ravi P. Nargund, Marcia M. Murphy, David B.R. Johnston, Arthur A. Patchett, Kang Cheng, Liente Wei, Wanda W.-S. Chan, Bridget Butler, Thomas M. Jacks, Gerard Hickey, Roy Smith. (1997) The synthesis and activity of spiroindane growth hormone secretagogues. Bioorganic & Medicinal Chemistry Letters 7:6, 663-668
CrossRef280
Thomas R. Hornick, Jerome Kowel. (1997) CLINICAL EPIDEMIOLOGY OF ENDOCRINE DISORDERS IN THE ELDERLY. Endocrinology & Metabolism Clinics of North America 26:1, 145-163
CrossRef281
Jean-Yves Reginster. (1997) Miscellaneous and Experimental Agents. The American Journal of the Medical Sciences 313:1, 33-40
CrossRef282
Janet Vittone, Marc R. Blackman, Jan Busby-Whitehead, Chris Tsiao, Kerry J. Stewart, Jordan Tobin, Tom Stevens, Michele F. Bellantoni, Marc A. Rogers, Gerhard Baumann, Jesse Roth, S.Mitchell Harman, Richard G.S. Spencer. (1997) Effects of single nightly injections of growth hormone—releasing hormone (GHRH 1–29) in healthy elderly men. Metabolism 46:1, 89-96
CrossRef283
Lars Ellegård, Ingvar Bosaeus, Svante Nordgren, Bengt-Åke Bengtsson. (1997) Low-Dose Recombinant Human Growth Hormone Increases Body Weight and Lean Body Mass in Patients with Short Bowel Syndrome. Annals of Surgery 225:1, 88-96
CrossRef284
O. Bouillanne, M. Rainfray, O. Tissandier, A. Nasr, A. Lahlou, X. Cnockaert, F. Piette. (1996) Growth hormone therapy in elderly people: an age-delaying drug?. Fundamental & Clinical Pharmacology 10:5, 416-430
CrossRef285
Jacek Pinski, Jan Izdebski, Andreas Jungwirth, Kate Groot, Andrew V. Schally. (1996) Effect of chronic administration of a new potent agonist of GH-RH(1–29)NH2 on linear growth and GH responsiveness in rats. Regulatory Peptides 65:3, 197-201
CrossRef286
Leona Cuttler. (1996) THE REGULATION OF GROWTH HORMONE SECRETION. Endocrinology & Metabolism Clinics of North America 25:3, 541-571
CrossRef287
David Hamerman, E. Richard Stanley. (1996) Implications of increased bone density in osteoarthritis. Journal of Bone and Mineral Research 11:9, 1205-1208
CrossRef288
S. E. Reid, M. S. Murthy, M. Kaufman, E. F. Scanlon. (1996) Endocrine and paracrine hormones in the promotion, progression and recurrence of breast cancer. British Journal of Surgery 83:8, 1037-1046
CrossRef289
H Tanaka. (1996) Does growth hormone treatment prevent corticosteroid-induced osteoporosis?. Bone 18:6, 493-494
CrossRef290
Xiaowei Xu, William E. Sonntag. (1996) Growth hormone and aging: Regulation, signal transduction and replacement therapy. Trends in Endocrinology & Metabolism 7:4, 145-150
CrossRef291
Judith B. Kosasih, Adil A. Abbasi, Daniel Rudman. (1996) Serum Insulin-Like Growth Factor-I and Serum Testosterone Status of Elderly Men in an Inpatient Rehabilitation Unit. The American Journal of the Medical Sciences 311:4, 169-173
CrossRef292
Laura C. Rall, Ronenn Roubenoff. (1996) Body composition, metabolism, and resistance exercise in patients with rheumatoid arthritis. Arthritis Care & Research 9:2, 151-156
CrossRef293
Torstein R. Meling, Eric S. Nylen. (1996) Growth Hormone Deficiency in Adults: A Review. The American Journal of the Medical Sciences 311:4, 153-166
CrossRef294
Abraham Z. Reznick, Eli Carmeli, Isaac Roisman. (1996) Effects of growth hormone on skeletal muscles of aging systems. AGE 19:2, 39-44
CrossRef295
Fazio, Serafino, Sabatini, Domenico, Capaldo, Brunella, Vigorito, Carlo, Giordano, Arturo, Guida, Raffaele, Pardo, Francesco, Biondi, Bernadette, Saccà, Luigi, . (1996) A Preliminary Study of Growth Hormone in the Treatment of Dilated Cardiomyopathy. New England Journal of Medicine 334:13, 809-814
Full Text296
Jeffrey J. Zachwieja, Gianna Toffolo, Claudio Cobelli, Dennis M. Bier, Kevin E. Yarasheski. (1996) Resistance exercise and growth hormone administration in older men: Effects on insulin sensitivity and secretion during a stable-label intravenous glucose tolerance test. Metabolism 45:2, 254-260
CrossRef297
Isao Shimokawa, Byung Pal Yu, Yoshikazu Higami, Takayoshi Ikeda. (1996) Morphometric analysis of somatotrophs: Effects of age and dietary restriction. Neurobiology of Aging 17:1, 79-86
CrossRef298
Laura J. Ghiron, Janice L. Thompson, Leah Holloway, Raymond L. Hintz, Gail E. Butterfield, Andrew R. Hoffman, Robert Marcus. (1995) Effects of recombinant insulin-like growth factor-I and growth hormone on bone turnover in elderly women. Journal of Bone and Mineral Research 10:12, 1844-1852
CrossRef299
S. S. C. YEN, A. J. MORALES, O. KHORRAM. (1995) Replacement of DHEA in Aging Men and Women.. Annals of the New York Academy of Sciences 774:1 Dehydroepiand, 128-142
CrossRef300
Per Björntorp. (1995) Neuroendocrine ageing. Journal of Internal Medicine 238:5, 401-404
CrossRef301
Beda Hartmann, Sylvia Kirchengast, Alexander Albrecht, Thomas Laml, Diana Bikas, Johannes Huber. (1995) Effects of hormone replacement therapy on growth hormone secretion patterns in correlation to somatometric parameters in healthy postmenopausal women. Maturitas 22:3, 239-246
CrossRef302
R. J. Erdtsieck, H. A. P. Pols, N. K. Valk, B. M. Ouwerkerk, S. W. J. Lamberts, P. Mulder, J. C. Birkenhäger. (1995) Treatment of post-menopausal osteoporosis with a combination of growth hormone and pamidronate: a placebo controlled trial. Clinical Endocrinology 43:5, 557-565
CrossRef303
Lin Chu, Helmut Mrozik, Michael H. Fisher, Jeannette E. Brown, Kang Cheng, Wanda W.-S. Chan, William R. Schoen, Matthew J. Wyvratt, Bridget S. Butler, Roy G. Smith. (1995) Aliphatic replacements of the biphenyl moiety of the nonpeptidyl growth hormone secretagogues L-692,429 and L-692,585. Bioorganic & Medicinal Chemistry Letters 5:19, 2245-2250
CrossRef304
Ken K.Y. Ho, David M. Hoffman. (1995) Defining growth hormone deficiency in adults. Metabolism 44, 91-96
CrossRef305
Harold N. Rosen, Vicki Chen, Antonio Cittadini, Susan L. Greenspan, Pamela S. Douglas, Alan C. Moses, Wesley G. Beamer. (1995) Treatment with growth hormone and IGF-I in growing rats increases bone mineral content but not bone mineral density. Journal of Bone and Mineral Research 10:9, 1352-1358
CrossRef306
Richard J Krieg, Fernando Santos, James C M Chan. (1995) Growth hormone, insulin-like growth factor and the kidney. Kidney International 48:2, 321-336
CrossRef307
Regina C. Casper. (1995) Nutrition and its relationship to aging. Experimental Gerontology 30:3-4, 299-314
CrossRef308
Diane B. Miller, Andrzej Bartke, James P. O'Callaghan. (1995) Increased glial fibrillary acidic protein (GFAP) levels in the brains of transgenic mice expressing the bovine growth hormone (bGH) gene. Experimental Gerontology 30:3-4, 383-400
CrossRef309
KAUP R. SHETTY, UMA P. RAO, KRISHAN L. GUPTA, DANIEL RUDMAN. (1995) Studies of Growth Hormone/Insulin-like, Growth Factor-I in Polio Survivors. Annals of the New York Academy of Sciences 753:1 The Post-Poli, 276-284
CrossRef310
Monika Gniadecka. (1995) Non-invasive methods for determination of oedema and water behaviour in the skin. Skin Research and Technology 1:2, 55-60
CrossRef311
Salem A. Beshyah, Patricia Kyd, Elizabeth Thomas, Angela Fairney, Desmond G. Johnston. (1995) The effects of prolonged growth hormone replacement on bone metabolism and bone mineral density in hypopituitary adults. Clinical Endocrinology 42:3, 249-254
CrossRef312
Dragan Micle, Vera Popovic, Aleksandra Kendereski, Djura Macut, Fellpe F. Casanueva, Carlos Dieguez. (1995) Growth hormone secretion after the administration of GHRP-6 or GHRH combined with GHRP-6 does not decline in late adulthood. Clinical Endocrinology 42:2, 191-194
CrossRef313
Nancy M. Wright, Josette Renault, Bruce Hollis, Norman H. Bell, Lyndon L. Key. (1995) Effect of growth hormone on bone: Bone mineral density, trabecular bone volume, and alkaline phosphatase improve or are restored in the dwarf rat treated with growth hormone. Journal of Bone and Mineral Research 10:1, 127-131
CrossRef314
Suresh I.S. Rattan. (1995) Ageing—A biological perspective. Molecular Aspects of Medicine 16:5, 439-508
CrossRef315
Salem A. Beshyah, Christopher Freemantie, Manjit Shahl, Victor Anyaoku, Stephen Merson, Sean Lynch, Elizabeth Skinner, Patrick Sharp, Rodney Foale, Desmond G. Johnston. (1995) Replacement treatment with biosynthetic human growth hormone in growth hormone-deficient hypopituitary adults. Clinical Endocrinology 42:1, 73-84
CrossRef316
M. GNIADECKA, J. SERUP, J. SONDERGAARD. (1994) Age-related diurnal changes of dermal oedema: evaluation by high-frequency ultrasound. British Journal of Dermatology 131:6, 849-855
CrossRef317
Q Zhai, Z Lai, P Roos, F Nyberg. (1994) Characterization of growth hormone binding sites in rat brain. Acta Paediatrica 83:s406, 92-95
CrossRef318
Clifford J. Rosen. (1994) Growth hormone, insulin-like growth factors, and the senescent skeleton: Ponce de Leon's fountain revisited?. Journal of Cellular Biochemistry 56:3, 348-356
CrossRef319
Sylvia Kirchengast. (1994) Body dimensions and thyroid hormone levels in premenopausal and postmenopausal women from Austria. American Journal of Physical Anthropology 94:4, 487-497
CrossRef320
Vito De Gennaro Colonna, Silvano G. Cella, Marco Parenti, Vittorio Locatelli, Daniela Cocchi, Eugenio E. Müller. (1994) Neuroendocrine aging: Its impact on somatotrophic function. Neurochemistry International 25:1, 5-10
CrossRef321
Charles V. Mobbs. (1994) Molecular hysteresis: Residual effects of hormones and glucose on genes during aging. Neurobiology of Aging 15:4, 523-534
CrossRef322
John E. Morley, James F. Flood, Andrew J. Silver, Fran E. Kaiser. (1994) Effects of peripherally secreted hormones on behavior. Neurobiology of Aging 15:4, 573-577
CrossRef323
Lawrence A. Frohman. (1994) A neuroendocrine overview of aging. Neurobiology of Aging 15:4, 479-484
CrossRef324
Ronald F. Wolf, Bruce Ng, Benny Weksler, Michael Burt, Murray F. Brennan. (1994) Effect of growth hormone on tumor and host in an animal model. Annals of Surgical Oncology 1:4, 314-320
CrossRef325
J. Oscarsson, M. Ottosson, O. Wiklund, P. Mårin, K. Vikman-Adolfsson, P. Björntorp, S. Edén. (1994) Low dose continuously infused growth hormone results in increased lipoprotein(a) and decreased low density lipoprotein cholesterol concentrations in middle-aged men. Clinical Endocrinology 41:1, 109-116
CrossRef326
O. Hardiman. (1994) Dystrophin deficiency, altered cell signalling and fibre hypertrophy. Neuromuscular Disorders 4:4, 305-315
CrossRef327
Hans de Boer, Geert-Jan Blok, Corrie Popp-Snijders, EduardA van der Veen, Adrian Williams, Tamara Harris, Ronenn Roubenoff, Douglas Kiel, Jean Langlois, Richard Havlik, Peter Wilson. (1994) Diagnosis of growth hormone deficiency in adults. The Lancet 343:8913, 1645-1646
CrossRef328
D.M Hoffman, A.J O'Sullivan, K.K.Y Ho, R.C Baxter. (1994) Diagnosis of growth-hormone deficiency in adults. The Lancet 343:8905, 1064-1068
CrossRef329
Torben Laursen, Jens O. L. Jørgensen, Jens S. Christiansen. (1994) Pharmacokinetics and metabolic effects of growth hormone injected subcutaneously in growth hormone deficient patients: thigh versus abdomen. Clinical Endocrinology 40:3, 373-378
CrossRef330
Salem A. Beshyah, Elizabeth Thomas, Patricia Kyd, Patrick Sharp, Angela Fairney, Desmond G. Johnston. (1994) The effect of growth hormone replacement therapy in hypopituitary adults on calcium and bone metabolism*. Clinical Endocrinology 40:3, 383-391
CrossRef331
E. Kirk Neely, M.D, Ron G. Rosenfeld, M.D. (1994) USE AND ABUSE OF HUMAN GROWTH HORMONE. Annual Review of Medicine 45:1, 407-420
CrossRef332
A. G. JOHANSSON, E. LINDH, S. LJUNGHALL. (1993) IGFs: function and clinical importance 4 Growth hormone, insulin-like growth factor I, and bone: a clinical review. Journal of Internal Medicine 234:6, 553-560
CrossRef333
LOUIS E. Underwood, P. BACKELJAUW. (1993) IGFs: function and clinical importance 6 Therapy with recombinant human insulin-like growth factor I in children with insensitivity to growth hormone and in catabolic conditions. Journal of Internal Medicine 234:6, 571-577
CrossRef334
John J. Kelly, Ivan A. Rajkovic, Anthony J. O'Sullivan, Conrad Sernia, Ken K. Y. Ho. (1993) Effects of different oral oestrogen formulations on insulin-like growth factor-I, growth hormone and growth hormone binding protein in post-menopausal women. Clinical Endocrinology 39:5, 561-567
CrossRef335
N. Meller, J. Møller, J. O. L. Jørgensen, P. Ovesen, O. Schmitz, K. G. M. M. Albert, J. S. Christiansen. (1993) Impact of 2 weeks high dose growth hormone treatment on basal and insulin stimulated substrate metabolism in humans. Clinical Endocrinology 39:5, 577-581
CrossRef336
Lester Cohn, Axel G. Feller, Michael W. Draper, Inge W. Rudman, Daniel Rudman. (1993) Carpal tunnel syndrome and gynaecomastia during growth hormone treatment of elderly men with low circulating IGF-I concentrations. Clinical Endocrinology 39:4, 417-425
CrossRef337
Malayappa Jeevanandam, Scott R. Petersen, Raymond F. Shamos. (1993) Protein and glucose fuel kinetics and hormonal changes in elderly trauma patients. Metabolism 42:10, 1255-1262
CrossRef338
R.J.O. Davies. (1993) Sleep and the lung: current issues in nocturnal respiratory research. Respiratory Medicine 87:7, 503-507
CrossRef339
David A. Fryburg, Eugene J. Barrett. (1993) Growth hormone acutely stimulates skeletal muscle but not whole-body protein synthesis in humans. Metabolism 42:9, 1223-1227
CrossRef340
Zhennan Lai, Paul Roos, Qingzhu Zhai, Yngve Olsson, Karin Fhölenhag, Christer Larsson, Fred Nyberg. (1993) Age-related reduction of human growth hormone-binding sites in the human brain. Brain Research 621:2, 260-266
CrossRef341
Ronald S. Swerdloff, Christina Wang. (1993) Androgens and aging in men. Experimental Gerontology 28:4-5, 435-446
CrossRef342
William R. Pendergrass, Yi Li, DeZhao Jiang, Norman S. Wolf. (1993) Decrease in cellular replicative potential in ?giant? mice transfected with the bovine growth hormone gene correlates to shortened life span. Journal of Cellular Physiology 156:1, 96-103
CrossRef343
Joan DiMartino-Nardi, Susan Wesoly, Lisa Schwartz, Paul Saenger. (1993) Lack of clinical evidence of sodium retention in children with idiopathic short stature treated with recombinant growth hormone. Metabolism 42:6, 730-734
CrossRef344
J. B. Koea, R. G. Douglas, J. H. F. Shaw, P. D. Gluckman. (1993) Growth hormone therapy initiated before starvation ameliorates the catabolic state and enhances the protein-sparing effect of total parenteral nutrition. British Journal of Surgery 80:6, 740-744
CrossRef345
JensO.L. Jrgensen, JensS. Christiansen. (1993) GROWTH HORMONE THERAPY. The Lancet 341:8855, 1247-1248
CrossRef346
Harald Kotzmann, Peter Bernecker, Peter Hübsch, Peter Pietschmann, Wolfgang Woloszczuk, Thomas Svoboda, Georg Geyer, Anton Luger. (1993) Bone mineral density and parameters of bone metabolism in patients with acromegaly. Journal of Bone and Mineral Research 8:4, 459-465
CrossRef347
JACEK PINSKI, TETSL YANO, KATE GROOT, JOZSEF ZSIGO, ZOLTAN REKASI, ANA MARIA COMARU-SCHALLY, ANDREW V. SCHALLY. (1993) Comparison of GH-stimulation by GH-RH(1-29)NH2 and an agmatine29 GH-RH analog, after intravenous, subcutaneous and intranasal administration and after pulmonary inhalation in rats. International Journal of Peptide and Protein Research 41:3, 246-249
CrossRef348
Robert G. Bing-You, Marie-Claire Denis, Clifford J. Rosen. (1993) Low bone mineral density in adults with previous hypothalamic-pituitary tumors: Correlations with serum growth hormone responses to GH-releasing hormone, insulin-like growth factor I, and IGF binding protein 3. Calcified Tissue International 52:3, 183-187
CrossRef349
Mark L. Hartman, Ali Iranmanesh, Michael O. Thorner, Johannes D. Veldhuis. (1993) Evaluation of pulsatile patterns of growth hormone release in humans: A brief review. American Journal of Human Biology 5:6, 603-614
CrossRef350
R. C. Cuneo, F. Salomon, G. A. McGauley, P. H. Sönksen. (1992) The growth hormone deficiency syndrome in adults. Clinical Endocrinology 37:5, 387-397
CrossRef351
A. G. JOHANSSON, P. BURMAN, K. WESTERMARK, S. LJUNGHALL. (1992) The bone mineral density in acquired growth hormone deficiency correlates with circulating levels of insulin-like growth factor I. Journal of Internal Medicine 232:5, 447-452
CrossRef352
S. M. Orme, J. P. Sebastian, B. Oldroyd, S. P. Stewart, P. J. Grant, M. H. Stickland, M. A. Smith, P. E. Belchetz. (1992) Comparison of measures of body composition in a trial of low dose growth hormone replacement therapy. Clinical Endocrinology 37:5, 453-459
CrossRef353
Robert M. Bennett, Sharon R. Clark, Stephen M. Campbell, Carol S. Burckhardt. (1992) Low levels of somatomedin C in patients with the fibromyalgia syndrome. A possible link between sleep and muscle pain. Arthritis & Rheumatism 35:10, 1113-1116
CrossRef354
Gerald Schulman. (1992) How Important Is the Problem of Malnutrition in Chronic Dialysis Patients?. Seminars in Dialysis 5:4, 263-265
CrossRef355
Susan M. Schwartz, Joseph W. Kemnitz. (1992) Age- and gender-related changes in body size, adiposity, and endocrine and metabolic parameters in free-ranging rhesus macaques. American Journal of Physical Anthropology 89:1, 109-121
CrossRef356
Amir Tavakkol, James T. Elder, Christopher E. M. Griffiths, Kevin D. Cooper, Harvinder Taiwar, Gary J. Fisher, Karen M. Keane, Susan K. Foltin, John J. Voorhees. (1992) Expression of Growth Hormone Receptor, Insulin-Like Growth Factor 1 (IGF-1) and IGF-1 Receptor mRNA and Proteins in Human Skin.. Journal of Investigative Dermatology 99:3, 343-349
CrossRef357
Steven W. J. Lamberts, Nick K. Valk, Arjen Binnerts. (1992) The use of growth hormone in adults: a changing scene. Clinical Endocrinology 37:2, 111-115
CrossRef358
S. LJUNGHALL, A. G. JOHANSSON, P. BURMAN, O. KÄMPE, E. LINDH, F. A. KARLSSON. (1992) Low plasma levels of insulin-like growth factor 1 (IGF-1) in male patients with idiopathic osteoporosis. Journal of Internal Medicine 232:1, 59-64
CrossRef359
A. H. Meier, A. H. Cincotta, W. C. Lovell. (1992) Timed bromocriptine administration reduces body fat stores in obese subjects and hyperglycemia in type II diabetics. Experientia 48:3, 248-253
CrossRef360
Mary Lee Vance. (1992) Growth hormone therapy in adults. Trends in Endocrinology & Metabolism 3:2, 46-48
CrossRef361
William M. Bennet, Morey W. Haymond. (1992) Growth hormone and lean tissue catabolism during long-term glucocorticoid treatment. Clinical Endocrinology 36:2, 161-164
CrossRef362
Michael N. Pollak, Hung The Huynh, Susan Pratt Lefebvre. (1992) Tamoxifen reduces serum insulin-like growth factor I (IGF-I). Breast Cancer Research and Treatment 22:1, 91-100
CrossRef363
James W. Pritchett. (1992) Human growth hormone in polymethyl methacrylate. Acta Orthopaedica 63:5, 520-522
CrossRef364
Helen M. Whitehead, Colin Boreham, Edwin M. Mcllrath, Brian Sheridan, Laurence Kennedy, A. Brew Atkinson, David R. Madden. (1992) Growth hormone treatment of adults withgrowth hormone deficiency: results of a 13-month placebo controlled cross-over study. Clinical Endocrinology 36:1, 45-52
CrossRef365
Annette Schlemmer, Julia S. Johansen, Saren A. Pedersen, Jens O. L. Jargensen, Christian Hassager, Glaus Christiansen. (1991) The effect of growth hormone (GH) therapy on urinary pyridinoline cross-links in GH-deficient adults. Clinical Endocrinology 35:6, 471-476
CrossRef366
P.H. SÖNKSEN, R.C. CUNEO, F. SALOMON, G. McGAULEY, C.M. WILES, P. WILMSHURST, C. BYRNE, R. HESP, C. LOWY, A. WEISSBERGER. (1991) Growth Hormone Therapy in Adults with Growth Hormone Deficiency. Acta Paediatrica 80:s379, 139-146
CrossRef367
Salem A. Beshyah, Victor Anyaoku, Rathnam Niththyananthan, Patrick Sharp, Desmond G. Johnston. (1991) The effect of subcutaneous injection site on absorption of human growth hormone: abdomen versus thigh. Clinical Endocrinology 35:5, 409-412
CrossRef368
Elaine Ron, Gloria Gridley, Zdenek Hrubec, William Page, Shobhit Arora, Joseph F. Fraumeni. (1991) Acromegaly and gastrointestinal cancer. Cancer 68:8, 1673-1677
CrossRef369
Munro Peacock. (1991) Interpretation of bone mass determinations as they relate to fracture: Implications for asymptomatic primary hyperparathyroidism. Journal of Bone and Mineral Research 6:S2, S77-S82
CrossRef370
C. Wüster, E. Slenczka, R. Ziegler. (1991) Erhöhte Prävalenz von Osteoporose und Arteriosklerose bei konventionell substituierter Hypophysenvorderlappeninsuffizienz: Bedarf einer zusätzlichen Wachstumshormonsubstitution?. Klinische Wochenschrift 69:16, 769-773
CrossRef371
RICHARD G. CUTLER. (1991) Human Longevity and Aging: Possible Role of Reactive Oxygen Species. Annals of the New York Academy of Sciences 621:1 Physiological, 1-28
CrossRef372
Roland T. Jung, Patrick Chong. (1991) The management of obesity. Clinical Endocrinology 35:1, 11-20
CrossRef373
O. M. Rutherford, D. A. Jones, J. M. Round, C. R. Buchanan, M. A. Preece. (1991) Changes in skeletal muscle and body composition after discontinuation of growth hormone treatment in growth hormone deficient young adults. Clinical Endocrinology 34:6, 469-475
CrossRef374
(1991) Growth hormone therapy in elderly people. The Lancet 337:8750, 1131-1132
CrossRef375
Francis Dumler. (1991) Impact of Nutritional Status on the Well Being of Hemodialysis Patients. Seminars in Dialysis 4:2, 72-74
CrossRef376
James J. Smith, Carol J.M. Porth. (1991) Posture and the circulation: The age effect. Experimental Gerontology 26:2-3, 141-162
CrossRef377
(1990) Effects of Human Growth Hormone in Men over 60 Years Old. New England Journal of Medicine 323:22, 1561-1563
Full Text378
Lee Vance, Mary, . (1990) Growth Hormone for the Elderly?. New England Journal of Medicine 323:1, 52-54
Full Text379
William A. Stini. (1990) “Osteoporosis”: Etiologies, prevention, and treatment. American Journal of Physical Anthropology 33:S11, 151-194
CrossRef
- Letters
